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Summary 
Mouse hepatitis virus (MHV) is a common infection in a large number of laboratory 
mouse colonies and is known to interfere with research results.   Serology testing is a 
good method of detecting the historical presence of MHV, however, it cannot detect 
when the mouse is currently shedding the virus. 
The purpose of this study was to develop an in-house Polymerase Chain Reaction (PCR) 
assay to detect MHV in naturally infected mice using faecal samples.  PCR is a highly 
sensitive test that can detect few copies of virus in a given sample.  The PCR was also 
used to detect the length of time MHV was shedding in C57BL6/J mice. 
A number of problems with cross-contamination were encountered and largely 
overcome.  Standard conditions for extracting RNA from faecal pellets, reverse-
transcribing it into cDNA and detecting the presence of viral sequences by PCR were 
developed. 
The pattern of viral shedding from “naïve” mice introduced into the animal facility was 
found to be variable, even between animals housed in the same cage. Not all animals 
appeared to shed virus at all and, of those that did, some showed more than one cycle 
of shedding within the observation period. 
Shedding was more consistent from post-weaning animals born from matings between 
members of the introduced cohort, but still with some variability. Not all animals had 
apparently cleared the virus at the end of the 30-day observation period. 
There was generally good correlation between the detection of viral sequences and the 
ultimate serological status of sample mice, with some notable exceptions. 
These results are discussed in the context of using PCR to evaluate the current “viral 
“load” in an animal facility and in developing strategies for elimination of the organism.  
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1 Introduction 
 Microbiological screening in animal units. 1.1
Animals are used by scientists in experiments as a vital part of advancement in 
scientific and medical research.  These animals are housed in specialist laboratory units 
in universities, medical schools and pharmaceutical companies etc.  The health status 
of these animals is very important and a programme of health monitoring is a vital part 
of the management of the facilities to ensure that the standard of animal health within 
them is maintained. 
1.1.1 Reasons for health screening of animal units 
There are a number of reasons why health screening is important in animal units. Some 
animal pathogens are zoonotic in man and may therefore be serious safety risks. Such 
organisms, for example lymphocytic choriomeningitis virus (LCMV) and hantaan virus, 
used to be fairly common in laboratory mice but have now been eradicated from most 
long-established colonies. Due to their potential impact on human health, however, 
they are still usually included in standard panels of organisms to be screened for. Proof 
of the absence of these organisms is often required for the import of laboratory animals 
into another country, for the same reason. 
Some organisms, while no serious threat to human health, can cause significant disease 
in animal species, and clearly must be excluded. If they are found to be present, then a 
variety of measures may have to be taken to eliminate them, perhaps even the 
complete termination of animal holding, fumigation of the facility and re-stocking with 
known “clean” animals. 
Other organisms may have only slight effects on overall animal welfare in normal 
circumstances but can interfere substantially with scientific experiments, e.g., by 
causing changes in behaviour, growth rate, relative organ weight and/or immune 
response.  In Mouse Parvovirus type 1 (MPV-1), for example, natural infections are 
generally asymptomatic, even for neonatal and immunocompromised mice (Smith, 
Jacoby et al. 1993; Jacoby and Ballgoodrich 1995).  However, MPV-1 affects processes 
linked to cell proliferation. Reported effects include direct modulation and dysfunction 
of T lymphocytes and altered patterns of rejection of tumor and skin allografts (Baker 
1998).  Another example of disease effecting animal experiments is Pneumonia virus of 
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mice.  The virus is asymptomatic in euthymic animals (Smith, Carrano et al. 1984), 
however, causes chronic pneumonia and death in athymic (nude) mice (Richter, 
Thigpen et al. 1988; Weir, Brownstein et al. 1988).  Exposure increases the 
susceptibility to diabetes induction by streptozotocin in BALB/cByJ male mice (Leiter, 
Le et al. 1988).  It also causes significant decreases in body weights of F344/NCr rats 
but not of B6C3F1 mice (Rao, Piegorsch et al. 1989).   
The use of animals of known biological tendencies is important in ensuring 
reproducibility of experimental results (Mahler (Convenor), Berard et al. 2014). These 
sub-clinical infections are particularly insidious as, without regular screening, their 
presence may otherwise go unnoticed.  Their potential to increase variability among 
animals that otherwise have been chosen to be as similar as possible (e.g., inbred 
mouse lines) can confound a scientific experiment or, at the very least, greatly increase 
the number of animals required for a significant result to be obtained. When the 
purpose of the experiment is, for example, to test the immune response to deliberately 
administered exogenous agent, the pre-existence of immunologically active organisms 
can completely confound the data. 
With novel lines of genetically modified animals having been created in scientific 
establishments around the world, the need to move animals between different 
establishments has grown significantly. Regular health screening can reduce the risk of 
spreading unsuspected microbial contaminants from one laboratory to another. 
1.1.2 Organisms that are screened for  
Most laboratories will use a standard panel of organisms to test for, to try to have some 
uniformity between them. In Europe, the panels most often used were devised by the 
Federation of European Laboratory Animal Associations (FELASA) (Mahler 
(Convenor), Berard et al. 2014) .  Table 1 below contains a list of infectious agents that 
FELASA recommends are monitored for and the frequency of monitoring, for 
laboratory mice. 
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Table 1: Recommended infectious agents to monitor and frequencies of monitoring for laboratory mice 
(Mus musculus) 
Viruses Every 3 months Annually 
Mouse Hepatitis virus X  
Mouse rotavirus X  
Murine norovirus X  
Parvoviruses: X  
   Minute virus of mice X  
   Mouse parvovirus X  
Theiler’s murine encephalomyelitis virus X  
Lymphocytic choriomeningitis virus X  
Mouse adenovirus type 1 (FL)  X 
Mouse adenovirus type 2 (K87)  X 
Mousepox (ectromelial) virus  X 
Pneumonia virus of mice  X 
Reovirus type 3  X 
Sendai virus  X 
Bacteria  X 
Helicobacter spp. 
If positive, speciation for H. hepaticus, H. bilis and H. typhlonius is 
recommended 
  
Pasteurella pneumotropica X  
Streptococci β-haemolytic (not in group D) X  
Streptococcus pneumonia X  
Citrobacter rodentium X  
Clostridium piliforme  X 
Corynebacterium kutscheri  X 
Mycoplasma pulmonis  X 
Salmonella spp.  X 
Streptobacillus moniliformis  X 
Parasites  X 
Endo- and ectoparasites (reported to the genus level)   
Additional agents* X  
Viruses:   
   Hantaviruses   
   Herpesviruses (mouse cytomegalovirus, mouse thymic virus)   
   Lactate-dehydrogenase elevating virus   
   Polyomaviruses (mouse polyomavirus, K virus)   
Bacteria and fungi:   
   Cilia-associated respiratory bacillus   
   Klebsiella oxytoca, Klebsiella pneumonia   
   Other Pasteurellaceae†   
   Pneumocystis murina   
   Pseudomonas aeruginosa   
   Staphylococcus aureus   
Others as necessary   
All agents listed should be reported if found in diagnostic examinations irrespective of when they are found. 
*Testing for these agents is optional and should be pursued if there is a specific need.  Frequency of testing will depend on 
local circumstances. 
†We acknowledge that the inclusion of the Pasteurellaceae family is controversial (this is a common bacteria which can cause 
respiratory disease, but usually doesn’t.  It is not definitive that they are always pathogenic or interfere with experiments). 
Screening for the family can be conducted should the facility wish, and the difficulty of some commercial kits to correctly 
identify Pasteurella pneumotropica, as well as the fluidity of the correct phenotypic classification, should also be 
acknowledged.  Table taken from (Mahler (Convenor), Berard et al. 2014) 
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Commercial suppliers usually offer animals that are rigorously monitored.  As just one 
example, Charles River carries out daily surveillance and careful monitoring of 
reproductive parameters.  Fortnightly tests are carried out, of environment samples by 
PCR and groups of animals by serology, for the most common agents. Every four weeks, 
TaqMan® PCR is used to screen 10 samples from environmental sites in the barrier 
rooms.  i.e., air exhaust grates and bedding disposal equipment.  They also perform 
serologic monitoring of 16 animals from each Specific Pathogen Free (SPF) mouse 
production room, testing the most prevalent viruses. 
In addition, every 13 weeks they evaluate 12-16 animals from three different age 
groups from each SPF area by a comprehensive health monitoring protocol including 
serology, bacteriology, parasitology, gross pathology and PCR for all Helicobacter spp. 
Each colony is also assessed annually by PCR for many common viruses, bacteria, fungi 
and parasites. 
The above information was obtained from Charles River’s technical sheet “Routine 
Health Monitoring of Charles River Rodent Barrier Production Colonies in Europe and 
North America”.  Colony health status reports are updated weekly on their website 
which includes any new colony status results. Table 2 is also taken from Charles River’s 
technical sheet and gives details regarding agents, frequency of testing and methods 
used.  It tests for all the infectious agents recommended on the FELASA list (Table 1) 
and some additional organisms. 
These “SPF / VAF (virus antibody-free) animals are of the usual status purchased by 
the University of Dundee and many other scientific establishments. However, Charles 
River, Harlan and other suppliers will also sell animals that have been bred in isolation 
and for which even more microbiological screening is done.  
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Table 2: Charles River table of agents tested for, method 
and frequency of testing 
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1.1.3 Methods for screening 
Traditionally, rodent viruses have been detected indirectly, by analysing blood samples 
(serology) for the presence of anti-viral antibodies. Screening methods include Enzyme 
Linked Immunosorbent Assay (ELISA) and Immunofluorescence Assay (IFA).  Viral 
antigen is immobilised on a plate or bead substrate and incubated with the blood 
sample. After washing, the substrate is then incubated with a fluorescence- or enzyme-
linked secondary antibody that binds to mouse antibodies. If the plate or bead becomes 
associated with above-background levels of fluorescence or enzyme activity, then the 
presence of antibodies to the virus is inferred and therefore it is concluded that, at 
some point in the past, the animal has been exposed to the virus (Figure 1).  This is 
performed by which one microbial antigen-antibody reaction is measured per well.  
Multiplexed Fluorometric ImmunoAssay (MFIA®), in comparison, is performed as a 
multiplexed assay.  Since the microspheres come in 100 distinct colour sets, as many as 
100 different assays can be performed simultaneously in a single microplate well. This 
innovation decreases the amount of serum, reagents and disposables required for 
routine testing while increasing the amount of information obtained from a single test 
well (Wunderlich, Dodge et al.) (Figure 2). 
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Figure 2:  MFIA Procedure.  The xMAP-based MFIA is a suspension microarray which 
utilizes color-coded polystyrene 5.6 micron beads to which antigens (or controls) are 
covalently linked. Since the beads come in 100 distinct color sets, as many as 100 
different assays can be performed in a single well Assay steps are performed in filter-
bottom microtiter plates so that beads can be washed by aspiration on a vacuum manifold. 
Reactions are read with the Luminex xMAP 100 fluorometer. The intensity of 
phycoerythrin fluorescence is reported as a median fluorescence index (MFI) 
(Wunderlich, Dodge et al.) 
Figure 1: Example of steps in ELISA test to determine if a particular antibody is present 
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Bacteria are usually screened for by direct culture and intestinal parasites by 
microscopic examination of a representative number of slides (looking for the 
organism itself, and/or the oocyst stage). 
Of course, serology does not work well in immune-deficient animals, nor does it allow 
one to conclude which animals are currently infected and actively shedding the virus. It 
requires expensive equipment and proprietary reagents to perform and is therefore 
normally sub-contracted to a specialist laboratory, though with inevitable delays and 
concerns about quality control. 
More recently, Reverse Transcriptase-coupled Polymerase Chain Reaction (RT-PCR) 
methods have been developed that detect the viral nucleic acid directly.  Viral RNA is 
first extracted, usually from mouse faecal samples (as MHV is usually an infection of the 
gastrointestinal tract, such samples should be a source of viral RNA) (Figure 3).  DNA 
that is complementary to a specific target area within the RNA (i.e. polymerse gene, N 
gene, M gene) is then created by reverse transcribing it using a suitable oligonucleotide 
primer and reverse transcriptase.  A region of the newly created DNA is then amplified 
by Polymerase Chain Reaction (PCR) (Figure 4). 
 
 
 
 
 
Collect faecal pellets from mice 
 
Figure 3: Total RNA extraction from mouse faecal pellets. 
Figure shows a typical RNA extraction using the Trizol method, adapted from 
www.bioneer.com 
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Table 3 below shows an example of a typical health screen carried out by a commercial 
diagnostic facility on sample mice in the Medical School Resource Unit (MSRU) at 
Ninewells Hospital, Dundee.  It lists what is being tested for, results of virology, 
microbiology, pathology, parasitology and the type of assay used for testing, positive 
results and number of animals tested.  Compared with the FELASA screen, it tests for 
all the recommended agents plus some extra ones, i.e. mouse polio virus, ciliary-
associated respiratory (CAR) Bacillus, Corynebacterium kutscheri, Encephalitozoon. 
cuniculi and enteric protozoa.  This particular report does not, however, indicate the 
frequency of testing. On this specific occasion, serologically positive tests for mouse 
Figure 4: Example of a Reverse-Transcriptase Polymerase Chain Reaction 
Flow of the process involved in a typical RT-PCR, taken from (Gilbert 
2013) 
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norovirus and enteric protozoa were obtained. However, the historical record also 
reveals the presence of mouse hepatitis virus (MHV) and endoparasites (almost 
certainly helminths),  
It is not practicable to test every one of many thousand mice in a facility, and therefore 
a system of representative sampling must be adopted. In the Ninewells unit, animals 
are sampled randomly from a number of the rooms. As the mice are housed in 
conventional grid-top cages, which are washed in a communal area (dirty cages are 
brought into the cage washing area through a dirty side, the dirty bedding is scrapped 
out and the cages are then placed in a conveyor belt tunnel washer, they are then filled 
with fresh sawdust and exit though a clean end) it is to be expected that an organism, if 
present at all, will manifest itself in samples from several rooms. 
Where mice are housed in individually ventilated cages, to isolate them from the 
microbiological environment of the main facility, (the cages are autoclaved before use 
together with bedding and food) the representative sampling is not possible, as each 
cage functions as an isolator. In this case “sentinel” animals are exposed to soiled 
bedding from these cages on a regular basis and then it is these animals that are tested. 
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Table 3: Example of typical health screen performed on mice from Medical School Resource Unit, at 
Ninewells Hospital, Dundee 
* dashes indicate not tested during specified period. 
 
 
Location:  DUNDEE NINEWELLS Main Unit         Sponsor: Dundee Univ Ninewells (J.Mcleod) 
Product: SPF Mice                     Reported: Tuesday, December 29, 2009 at 7:42 
                                                                                                                                   Most Recent                  Past 24 Months 
Summary Item                     Primary Assay       Year-Week *    Positive/Tested      Positive/Tested    
Virology 
Sendai Virus (SEND) MFIA/ELISA 2009-51 0/ 6    0 / 140 
Pneumonia Virus of Mice (PVM) MFIA/ELISA 2009-51 0/ 6    0 / 140 
Mouse Hepatitis Virus (MHV) MFIA 2009-51 0/ 6  42/ 150 
Minute Virus of Mice (MVM) MFIA 2009-51 0/ 6    0/ 140 
Mouse Parvovirus (MPV) MFIA 2009-51 0/ 6    0/ 140 
Murine Norovirus (MNV) MFIA 2009-51 2/ 6  43/ 140 
Mouse Polio Virus (TMEV (GDVII)) MFIA 2009-51 0/ 6    0/ 140 
Reovirus (REO) MFIA/ELISA 2009-51 0/ 6    0/ 140 
Mouse Rotavirus (EDIM) MFIA 2009-51 0/ 6    0/ 141 
Lymphocytic Choriomeningitis Virus MFIA/ELISA 2009-51 0/ 6    0/ 140 
Edromelia Virus (ECTRO) MFIA 2009-51 0/ 6    0/ 140 
Mouse Adenovirus (MAV) MFIA/ELISA 2009-51 0/ 6    0/ 140 
Mouse Cytomegalovirus (MCMV) MFIA 2009-51 0/ 6    0/ 140 
Mouse Pneumonitis Virus (K) MFIA 2009-51 0/ 6    0/ 140 
Polyma Virus (POLY) MFIA 2009-51 0/ 6    0/ 140 
Hantaan Virus (HANT) MFIA 2009-51 0/ 6    0/ 140 
Mouse Thymic Virus (MTLV) IFA 2009-25            0/42    0/ 132 
Microbiology 
B.bronchiseptica Culture 2009-51 0/ 6   0/ 103 
CAR Bacillus MFIA/ELISA, PCR 2009-51 0/ 6   0/ 140 
C.rodentium Culture 2009-51 0/ 6   0/ 103 
C.kutscheri Culture 2009-51 0/ 6   0/ 103 
H.bilis PCR        -- 
H.hepaticus PCR        -- 
Helicobacter sp. PCR        -- 
Klebsiella spp. Culture 2009-51 0/ 6   0/ 103 
M.pulmonis MFIA/ELISA, PCR 2009-51 0/ 6   0/ 140 
Pasteurellacae Culture 2009-51 0/ 6   0/ 103 
Ps.aeruginosa Culture 2009-51 0/ 6   0/ 103 
Salmonella sp. Culture 2009-51 0/ 6   0/ 103 
Staph.aureus Culture 2009-51 0/ 6   0/ 103 
S.moniliformis Culture 2009-51 0/ 6   0/ 103 
Beta Strep. Spp Culture 2009-51 0/ 6   0/ 103 
Strep.pneumonia Culture 2009-51 0/ 6   0/ 103 
Pathology 
Gross Exam Necropsy 2009-51 0/ 6   0/ 103 
Parasitology 
E.cuniculi MFIA/ELISA 2009-51 0/ 6   0/ 140 
Ectoparasites Exam 2009-51 0/ 6   0/ 103 
Endoparasites Exam 2009-51 0/ 6   1/ 103 
Enteric Protozoa Exam 2009-51 2/ 6  13/ 103 
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1.1.4 History of the Medical School Resource Unit 
The Medical School Resource Unit (MSRU) at Ninewells Hospital was built with the 
hospital in the early 1970s, and over the past 40 years has been host to a wide range of 
large and small animal species, ranging from pigs and sheep to small rodents and frogs.  
Currently, the Unit has permanent holdings of mice and rats only. There are 
approximately 20 animal holding rooms. The majority of the animals are housed in 
conventional grid-top cages (Figure 5), with no significant microbiological barrier 
between cages in the same room and only a limited barrier (created by operating the 
holding rooms at negative air pressures with respect to the common corridors) 
between one room and the next. All the used cages are cleaned and re-stocked in a 
common cage-washing area. Some mice are kept in individually ventilated cages (IVCs) 
(Figure 5), in which the air is delivered to and extracted from each cage via HEPA 
filters. Each IVC therefore operates as a micro-isolator, with a very high barrier even 
between cages on the same rack. Some animals are kept in positively pressured IVCs 
primarily to keep them free from micro-organisms that might be present in the 
conventionally-housed stocks. Others are kept in specially sealed negative-pressure 
systems, usually because they have been imported from elsewhere and they are to be 
used as donors for the collection of sperm or embryos for rederivation into a “clean” 
unit elsewhere. 
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A B
Figure 5: Examples of cage types used in Medical School Resource Unit, Ninewells Hospital 
A - Shows typical example of open-top grid cage (North Kent Plastics M1); B - Shows a typical individually ventilated cage 
(Techniplast) 
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1.1.5 Micro-organisms found in the MSRU 
The mouse stocks in the unit, which make up the great majority of the animals and 
most of which are in breeding programmes, routinely test positive for mouse norovirus 
(MNV), mouse hepatitis virus (MHV), Helicobacter spp., Pasteurella spp., and a variety 
of intestinal parasites including Syphacia spp., (pinworm) and Entamoeba. There may 
also be some commensal bacteria that are shared with humans, such as Staphylococcus 
spp., and Klebsiella spp. Of these agents, the MNV, Pasteurella, commensals and 
Entamoeba are not really regarded as being threats to human or animal welfare, nor 
are they likely to confound the types of research undertaken in the resource unit. While 
mouse norovirus is genetically related to the human virus responsible for outbreaks of 
diarrhoea and vomiting (most famously on cruise ships and in hospital wards), it is 
neither transmissible to humans nor does it cause outward signs of disease in mice 
unless its host is completely immune-deficient (Karst, Wobus et al. 2003), i.e. without 
either innate or acquired immunity. Pinworm could be a research problem, as it has the 
potential to cause low-grade inflammation of the gut (Taffs 1976), and can effect 
experimental results.  Unusual autoimmune responses were linked to infestation with a 
common rodent pinworm (Agersborg, Garza et al. 2001). But again this has not been 
found to be a serious problem in practice. While pinworm is easily killed by feeding the 
animals on a diet containing a benzimidazole anti-helminthic drug, e.g., fenbendazole, 
the oocyst stage of the organism’s life-cycle is highly resistant to most disinfectants, 
dehydration, autoclaving and other cleaning regimes. Re-infection after drug treatment 
is thus a very common finding. Indeed, in the late 2000s, while the MSRU was being 
refurbished, a determined effort was made to eradicate this organism but, after two 
years of apparently negative screens, it was soon detected once more. 
MHV, on the other hand, has a history of causing serious disease in infant and 
immunodeficient mice.  In infant mice clinical signs include diarrhea, poor growth and 
death and immunodeficient mice develop a wasting syndrome characterized by severe 
generalized disease and eventual death (Uetsuka, Nakayama et al. 1996). MHV is also 
capable of confounding scientific data even when its outward effects are much less 
significant.  Some examples of interference with research include:   
Contamination of transplantable tumours (Wunderlich, Dodge et al.) 
Rejection of human xenografts(Kyriazis, DiPersio et al. 1979) 
Altered response to chemical carcinogens (Barthold 1986a) 
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Immunodepression and immunostimulation depending on the time of infection 
(Virelizier, Virelizier et al. 1976) 
Decrease of the incidence of diabetes in non-obese diabetic mice (Wilberz, Partke et al. 
1991) 
 
1.1.6 The accidental introduction of MHV into the MSRU 
For about the last twenty years, the MSRU has operated an apparently robust policy on 
the import of animals from other establishments. In particular, documentation has 
always had to be produced to demonstrate that the facilities from which the animals 
are to come are apparently free from all significant micro-organisms, other than those 
that are already known to be present. The commercial suppliers of laboratory rodents 
match this requirement as a matter of routine. However, not all imports from other 
research organisations have been approved. 
In 2004, the resource unit took delivery of mice from another academic establishment, 
which had provided the necessary documentation in advance. However, between the 
last screen being done at that establishment and the mice arriving in the MSRU, MHV 
contamination entered. As soon as that establishment realised the fact, the manager of 
the MSRU was contacted and samples for MHV analysis were immediately sent away 
for testing. Initial results were negative but, because of the potential seriousness of the 
situation, animals were re-screened and positive results were reported. As the 
imported animals had been housed in conventional grid-top cages, there was little 
hope that the contamination was confined to only that room and, indeed, more 
extensive testing revealed the organism to be present throughout the resource unit. 
1.1.7 Potential strategies for eradication 
The definitive method for eradicating MHV is to kill all the susceptible animals, 
fumigate the entire facility and then re-stock. However, as the particular strain did not 
appear to be associated with some of the more severe effects associated with MHV 
infection, and this strategy would have halted all research work within the resource 
unit and eliminated some valuable mouse lines that would not easily be found from 
elsewhere, this option was rejected by the scientific community, the veterinary surgeon 
and the unit management. 
Since it appeared that infection was readily survivable, an alternative “firewall 
strategy” was considered in some detail. The principle is to halt the import of all non-
infected animals and the breeding of all lines already present in the unit. Once every 
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susceptible animal has become infected and then eliminated the virus (though it will 
now be sero-positive for anti-viral antibodies), the infection may be considered to have 
“burned itself out”. The period of time over which these draconian measures must be in 
place has been variously estimated as between six and 12 weeks. However, one would 
have to be absolutely certain that the virus had gone before allowing breeding to 
restart and for animals to be ordered from the usual suppliers once more. While it 
might have preserved the work of scientists who did not need to breed any animals, the 
great majority of the mouse lines in the unit were in breeding programmes and 
therefore the risk of losing valuable lines through not being able to produce the next 
generation would have been highly significant, particularly if the firewall had to be in 
place for a protracted period. 
Success or failure of the firewall strategy would have depended on knowing the life-
cycle of the precise viral strain circulating in the unit, so as to be able to calculate the 
“burnout period”. It would also have required access to a test for the presence of the 
virus itself (rather than the historical data produced by serology), that could be applied 
very quickly and economically to large numbers. PCR-based tests were in their infancy 
at the time so it would not have been feasible to deploy them. Because of the lack of 
robust evidence that the particular viral strain was causing any welfare issues or 
confounding any of the specific research projects current in the unit, again it was 
decided not to attempt the firewall strategy but to allow the infection to become 
enzootic in the conventionally-housed mouse colonies. However, some imported lines 
have been housed in IVCs successfully, without their apparently becoming infected. 
1.1.8 Current practice of the animal unit 
The animal unit at Ninewells Hospital does not currently accept mice from any other 
academic establishment into conventional housing without first isolating them in IVCs 
and determining the precise microbiological status of the animals actually supplied.  
This practice is not a general distrust in the management of academic facilities, it 
simply acknowledges that, as part of their normal business, they frequently import 
animals from other sites and therefore are at risk of the type of event that befell the 
MSRU. 
 
 
17 
 
 Mouse hepatitis virus 1.2
1.2.1 Transmission of the virus 
MHV is one of the most common viruses found in laboratory mouse colonies 
(Homberger, Zhang et al. 1998) and there have been numerous reports documenting 
its potential to interfere with research in both immunocompromised and 
immunocompetent mice.  MHV may be transmitted through aerosols, fomites (fur, 
dander, etc.) and direct contact (Wilberz, Partke et al. 1991).  The virus is highly 
contagious, although not persistent in the environment.  MHV may also contaminate 
cell cultures and transplantable tumours (Nicklas, Kraft et al. 1993).  Infection in 
immunocompetent mice can be asymptomatic (Compton, Barthold et al. 1993), as it 
appears to be in the MSRU.  Expression of the disease depends on the age, genotype, 
sanitary status, and experimental status of the mouse and the tropism and virulence of 
the infecting strain of the virus (Barthold, Beck et al. 1993).  In enzootic colonies, the 
infection survives amongst newly weaned animals, as these have lost the maternal 
passive immunity but have not yet developed a robust anti-viral immune reaction 
themselves. (Baker 1998).  “Nude” athymic mice (which have essentially no adaptive 
immune response) infected with MHV develop a wasting disease with high morbidity 
under natural conditions (Kunita, Terada et al. 1992). 
1.2.2 Detection of virus 
Traditionally, MHV screening has relied on the detection of anti-viral antibodies in a 
sample of blood (serology, as above), usually carried out by commercial companies 
which can be expensive.  Often, the sampled mice are “sentinels”, i.e. animals originally 
known to be negative for such antibodies but which have been exposed to soiled 
bedding from the cages being screened.  This allows many cages to be screened by the 
analysis of relatively few animals.  Presence of anti-viral antibodies (extracted from 
MHV infected cells) indicates that the animal has been exposed to MHV in the past, but 
not necessarily that it has an active infection.  Serology assays have the disadvantage of 
requiring a waiting period of several weeks for an immune response to develop 
(seroconversion).  Newly infected animals, or those in which the infection has reached 
its peak, will not necessarily have seroconverted yet and may be reported as negative. 
Many testing laboratories require that the tested animals have been in potential 
contact with the relevant organism for six weeks or longer, to enhance the chances that 
they have indeed become infected and mounted a strong immune response. Serological 
which is then run on an electrophoresis gel (typically 1.5% agarose) to check if the  
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testing is not reliable for screening immunodeficient mice directly (Casebolt, Qian et al. 
1997). 
More recently, nucleic acid-based tests for many of the organisms on the standard 
panels have been developed, as described above. 
Primers that will hybridise to opposite strands either side of the region to be amplified 
(i.e. Polymerse gene, N gene, M gene) are mixed with the DNA in a suitable chemical 
buffer solution, containing deoxy-ribonucleoside triphosphates (dNTPs, the building 
blocks from which the DNA polymerase synthesizes a new strand of DNA) and a DNA 
polymerase. Chemicals such as dimethyl sulfoxide (DMSO), which inhibits secondary 
structures and improves amplification of GC rich regions which further increase the 
amplification of the targeted sequence, and Bovine Serum Albumin (BSA) which aids 
PCR in the presence of inhibitors such as tannic acids (found in foods), or extracts from 
faeces, are often added as well. In the first cycle, the two-stranded DNA “template” is 
denatured and then allowed to hybridise to the primers. Extension from these sites 
then produces four strands from the original two. In subsequent cycles, this repeats, 
resulting in an approximate doubling of the amount of DNA corresponding to this 
defined region, eventually resulting in enough product for visualisation on an 
electrophoresis gel. 
The denaturation step involves heat, but the use of a heat-stable DNA polymerase (e.g., 
Taq, derived from the thermophilic bacterium Thermophilus aquaticus) means that 
many cycles can take place without the need to add new reagents to the tube. A thermal 
cycler is used to heat and cool the samples to the temperatures required for each step 
of the reaction.  An initial denaturing is carried out by heating the sample to a high 
temperature for approximately 1-3 minutes, this is essential to completely separate the 
strands of the template DNA by breaking the hydrogen bonds between them, at the 
beginning of the PCR run to ensure efficient utilization of the template during the first 
amplification cycle. The reaction then starts with a denaturation step whereby the 
sample is heated to a high temperature for 20-30 seconds.  The temperature is then 
lowered to a medium temperature for 20-30 seconds to allow annealing of the primers 
to the single stranded DNA.  The temperature is then increased again for the elongation 
step of the PCR.   At this stage the DNA polymerase synthesizes a new DNA strand 
complementary to the DNA template strand.  These steps are then repeated 25-40 
times in order to produce thousands of copies of the DNA fragment.  A final elongation 
time is then performed during the last cycle for 5-15 minutes to ensure any remaining 
single-stranded DNA is fully extended.  A dye is then added to the resulting product 
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amplified fragment does indeed have the expected size.  A DNA ladder which contains 
DNA fragments of known size is also added to the gel to compare with the size of the 
sample. 
The complete PCR procedure is now commonly used in research laboratories for a 
variety of purposes including the detection and diagnosis of infectious diseases.  In 
contrast to serological assays, PCR assays can indicate which animals are shedding 
virus at the time of sampling, but not those that may have been infected in the past but 
are currently free from the virus.  The turnaround time is also much faster than 
serology testing. 
1.2.3 Virus structure and life cycle 
MHV (figure 6) belongs to the coronaviridae family of enveloped viruses. It has a 31kb 
single stranded positive RNA genome (Lai 1990) which is divided into 7 genes (figure 
7). “Positive” indicates that the viral RNA can be translated directly into proteins in the 
infected cell.  The first gene (polymerase) is 22kb long, a non-structural protein 
encompassing more than two-thirds of the length of the genome and believed to 
encode the RNA-dependent RNA polymerase (Pachuk, Bredenbeek et al. 1989).  The 
functions of the other non-structural proteins remain unknown and each of them has 
been found missing in at least one virus strain suggesting that they are not essential for 
MHV replication (Yokomori and Lai 1991).  Gene 2 encodes the 30kD non-structural 
protein, gene 2-1 codes for the haemagglutinin/Esterase (HE) protein which is present 
in some MHV strains (Homberger 1997).  In MHV-A59, however, the HE gene is not 
expressed: its dedicated mRNA, mRNA 2-1, is not produced because of a mutation in 
the “transcription-regulating sequence” (de Groot 2006).  Gene 3 encodes the spike (S) 
protein.  It is usually cleaved into two subunits, S1 and S2 (Sturman, Ricard et al. 1985).  
S1 is responsible for receptor binding and S2 for membrane fusion (Bosch, van der Zee 
et al. 2003).  Gene 4 encodes a 15kD non-structural protein.  Gene 5 contains two open 
reading frames 5a and 5b.  5a encodes a 13 kD non-structural protein and 5b the small 
membrane protein (E) (Homberger 1997).  The small membrane protein (E) may play 
a role in either uncoating or assembly of the virus (Yu, Bi et al. 1994).  Gene 6 encodes 
the membrane (M) protein.  It is the most abundant envelope protein component 
having essential functions in virus assembly (Raamsman, Locker et al. 2000).  Gene 7, 
the nucleoprotein (N) is a major structural component of virions that associates with 
genomic RNA to form a long, flexible, helical nucleocapsid.  Interaction with the M 
protein leads to the formation of virus particles.  It may play roles in viral transcription, 
translation, and/or replication (Ning, Lakatoo et al. 2003). 
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Figure 7: RNA Genome 
1.Polymerase gene, 2. Non-structural protein, 2-1. Haemagglutinin/Esterase protein (some MHV strains), 3. Spike (S) 
protein, 4. Non-structural protein, 5a. Non-structural protein, 5b. Small membrane protein (E), 6. Membrane protein (M), 
7. Nucleoprotein (N) 
Figure 6: Structure of Mouse Hepatitis Virus 
Taken from www.lookfordiagnosis.com 
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The virus replicates in the cytoplasm of infected cells. (Figure 8). 
 
 
(Bergmann, Lane et al. 2006) 
 
Infection starts as the spike protein first binds to receptors (MHVR-1) on the cell 
surface (Lai and Cavanagh 1997). The viral envelope then fuses with the cell membrane 
and the nucleocapsid is introduced into the cytoplasm of the host cell (Krzystyniak and 
Dupuy 1984).  The first step of replication involves the translation of the genomic RNA 
to produce a viral RNA-dependent RNA polymerase, which can then copy the genetic 
material (Adami, Pooley et al. 1995).  By discontinuous leader-primed transcription the 
seven mRNAs are then generated.  Virus assembly takes place when the nucleoprotein 
binds to the genomic RNA to form the nucleocapsid, which in turn associates with 
aggregates of M proteins in the Golgi membranes. While the virus buds into the lumen 
of the Golgi apparatus host cell proteins in the lipid bilayer are replaced by virus 
Figure 8: Life cycle of Mouse Hepatitis Virus 
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glycoprotiensthis.  The virus is then released from the host cell by exocytosis or by 
cytolysis  (Homberger 1997).   
Several MHV strains can be recognised immunologically and by their tissue tropism, 
enterotropic and polytropic (Homberger, Zhang et al. 1998).  Primary infection causes 
respiratory disease, hepatitis and enteritis.  Enterotropic MHV strains are usually  
restricted to the intestine, with little dissemination to other organs (Casebolt, Qian et 
al. 1997) and are considered to be the most common form of natural infection 
(Barthold, Beck et al. 1993). As a result, virus is readily shed in the faeces. Infections  
can cause lesions in the intestine, variable levels of epithelial cell lysis and wasting 
away of villi in the terminal small intestine (Percy 2007). 
Despite the clear distinction in pathology, nobody yet has found a way to differentiate 
between enterotropic and polytropic MHV strains in vitro.  Comparison of the genome 
of enterotropic and polytropic MHV has not revealed a common distinguishing 
denominator.  Most likely the tissue tropism determinant is located on one of the 
structural proteins, and is influencing the virions’ ability to interact with the target cell 
(Homberger 1997). 
Since some forms of MHV can cause serious disease and even mild infections have the 
potential to interfere with the collection of robust scientific data, most mouse breeding 
establishments will attempt to exclude it by having stringent constraints on the import 
of animals from other sources.  The continued absence of the organism is then 
confirmed by regular screening, normally as part of tests for a range of pathogens. 
 
1.2.4 Previous Studies 
In the mid-20th century, MHV was studied as a model virus infecting mammalian 
systems (reviewed in (Weiss and Leibowitz 2011)).  A number of strains were 
identified with different infectivity and virulence and attempts were made to 
understand the molecular bases of these properties in cell cultures and in animals. 
Although the proteins on the virus surface (and their encoding RNA sequences) were 
found to be quite variable, more highly conserved genes were identified and targeted 
for the development of tests that would react against all strains of MHV. 
 The N protein (mRNA 7), situated towards the 3’end of the MHV viral genome, is the 
major structural component of virions and associates with genomic RNA to form a long, 
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flexible, helical nucleocapsid.  This then interacts with the M protein, leading to the 
formation of mature virus particles.  The N protein may play additional roles in viral 
transcription and translation, and/or replication (Ning, Lakatoo et al. 2003). 
In the early 1990s, a Japanese group (Kunita, Terada et al. 1992) showed that N genes 
of MHV strains MHV-A59 and MHV-JHM possessed more than 92% nucleotide 
sequence homology and all sub-genomic mRNAs in infected cells shared the N gene 
sequence, making this a likely target for a PCR assay that would commonly be 
applicable to all the MHV stains with sufficient specificity and sensitivity.  They 
compared the N genes of five strains of MHV and chose the primer sites for detecting 
MHV from the region of complete sequence conservation near the 3’end of the N gene.  
(Yamada, Yabe et al. 1998) also targeted the N gene to diagnose MHV using Nested                               
PCR (figure 9).  Primer location and sequences were based on the published MHV-
JHMV mRNA 7 sequence (Skinner and Siddell 1983).   
 
 
(Yamada, Yabe et al. 1998) 
Other areas that were targeted were the polymerase gene (Casebolt, Qian et al. 1997) 
and membrane protein M (F R Homberger 1991).  These are also highly conserved 
Figure 9: Primer location in the MHV mRNA 7 (N gene) 
Primers used by (Yamada, Yabe et al. 1998) to carry out Nested PCR targeting 
the N gene 
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regions of the viral genome.  They exhibit high sequence homology among different 
MHV strains (F R Homberger 1991). 
Previous sequencing by a commercial organisation of a PCR fragment from the N gene 
region of the genome of the virus circulating in the MSRU revealed a very close 
similarity with the A59 strain of MHV. (Figure 10)  
 
  
 
Even closer similarity with the N gene of a related virus, Puffinosis, a disease of manx 
shearwaters was in fact observed, though this was only as a result of nucleotide 
identities at one or two additional positions.  As this is also a coronavirus, which is 
related to MHV (Nuttall and Harrap 1982) this could explain the close similarity. 
It was decided that this study would also target the N gene as a site for amplification.  
Initially, the primers that were used were taken from a paper describing the use of PCR 
in the detection of MHV in an outbreak in a colony of immunodeficient mice (Yamada, 
Yabe et al. 1998).  It was also initially thought that a second round of PCR would be 
required to be performed using another set of primers which targets a region within 
the first region (nested PCR).  Nested PCR increases sensitivity, specificity and reduces 
amplification of unexpected primer sites.  However, most of these studies were carried 
out in the 80’s and 90’s when PCR was in its infancy.  With the advancement of new 
technology nested PCR might be too sensitive to even minute cross-contamination of 
the samples.   
Viral RNA was extracted from faecal samples as these are easy to obtain non-invasively.  
This method was used by (Casebolt, Qian et al. 1997), (Yamada, Yabe et al. 1998) and 
Figure 10: Comparison of N gene region of coronavirus circulating in the Medical School Resource Unit, 
Ninewells Hospital 
The sequencing, done by a commercial company shows a 94% homology to MHV A59 
Query = Sample from MRSU Sbjct = Part of N gene of MHV A59 
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(Oyanagi, Kato et al. 2004).  Some researchers used tissue samples (Wang, Campbell et 
al. 1999).  Tissue samples of 94 mice were tested from suspected MHV infected non-
nude mice, but positive results were only obtained in 8% of colon samples and 5% of a 
mixed sample of colon and liver.  No positive results were obtained from faecal 
samples.  When a nude mice was placed in the same cages with other non-nude mice or 
placed in cages with used dirty bedding, increased positivity was obtained, 10 out of 12 
colon samples were positive (83%), and only 5 out of 10 faecal samples were positive 
(50%), however, the animal is required to be killed to collect the tissues.  Choosing the 
correct time of testing is also an important consideration.  Most laboratories agreed 
that the virus was rapidly cleared by immunocompetent mice and MHV genome may 
only be detectable in the period 3-21 days after inoculation. 
 Aims and Objectives 1.3
While the MHV strain circulating in the MSRU is not causing serious concern with 
respect to either animal welfare or the validity of current research projects, it is 
understandably almost impossible for researchers to share their animals with other 
laboratories. Certain types of research not currently undertaken in that unit, for 
example studies of the immune system, might be more seriously affected by the 
presence of the organism. 
While the balance is still not in favour of a complete cull, fumigation and re-stocking 
(see above), a firewall strategy might still be worth attempting if much more were 
known about the life-cycle of the specific strain, how this might be affected by the 
different mouse strains in use and if a robust, inexpensive and rapid test for the 
presence of the virus itself were available. While PCR tests are now available from 
commercial suppliers, samples would still have to be collected, sent away, analysed and 
reported before actions could be taken on the basis of the data set. It might also not be 
affordable to test the number of samples necessary to be sure that the virus had indeed 
“burned out” before allowing the resumption of breeding. 
The aim of this research project was to develop and validate a fast, easy and reliable 
method of testing for MHV, using an in-house PCR-based test. Furthermore, it was 
intended to use this test to begin to understand the life-cycle of the virus in the MSRU 
in order to evaluate the likely success or otherwise of a firewall strategy for its 
elimination. 
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2 Materials and Methods 
 Animals 2.1
C57BL/6J mice were obtained from Charles River Laboratories (UK) Ltd., at their 
“SPF/VAF” microbiological status. The supplier declared that the animals showed no 
evidence of previous exposure to MHV, among other organisms. The Charles River 
colony is periodically refreshed with animals from the Jackson Laboratories (Bar 
Harbor, USA), the “home” of the definitive C57BL/6J line. In some pilot experiments, 
samples were taken from other animals in the MSRU and other resource units in the 
University, but these too were on the same genetic background. 
Five female and five male mice were received from Charles River at 6-8 weeks of age 
and housed in these two sex-matched groups. After the first phase of sample collection 
had been completed, three permanent mating pairs were set up. All animals were 
housed in conventional grid-top cages in a room in the facility that also accommodated 
several resident mouse colonies and were cared for by standard husbandry methods. A 
standard aspen sawdust substrate was used and RM1 diet (SDS Laboratories) and 
clean tap-water were provided ad libitum. Cages were changed weekly, with the cage 
bases being washed at high temperature but not autoclaved. 
As the faecal pellet collection would not cause any significant pain, suffering, distress or 
lasting harm, and otherwise the animals received entirely standard care, the project did 
not fall under the authority of the Animals (Scientific Procedures) Act 1986. There 
were no untoward welfare issues throughout the project. At its end, all the animals 
were killed, with blood samples being collected post mortem from some of them for 
serological analysis (see below). 
 Faecal Collection 2.2
Mice were placed in a clean beaker until a sufficient number of faecal pellets were 
excreted.  Pellets were then placed in a 2.0ml Eppendorf tube using clean tweezers and 
immediately put on ice. They were then either stored at -80°C or processed for RNA 
extraction immediately. 
 
 
27 
 
 
 RNA Extraction –  Qiagen Viral RNA Mini Kit (52904) 2.3
Buffers AVL, AW1 and AW2 were provided by the manufacturer of the kit. 
Faecal samples were suspended in 1.5ml of 0.89% NaCl, scissor minced and 
centrifuged at 4000 x g using Eppendorf Centrifuge 5415R for 20 minutes.  
Supernatant was then filtered using 0.22µm filter (Sarstedt 83.1826-001), 140µl of 
each filtered sample were added to 560µl of prepared Buffer AVL containing carrier 
RNA in a 1.5ml micro-centrifuge tube and mixed by pulse-vortexing for 15 seconds.  
The samples were then incubated at room temperature for 10 minutes, then briefly 
centrifuged to remove drops from the inside of the lid.  100% Ethanol (VWR 
20821.330) was added (560µl) to each sample and they were pulse-vortexed for 15 
seconds.  Each sample, buffer and ethanol solution (630µl) were then added to the Mini 
columns (in 2ml collection tubes) without wetting the rim.  They were then centrifuged 
at 6000 x g for 1 minute.  The Mini columns were then placed into clean 2ml collection 
tubes, and the tubes containing the filtrate were discarded.  The samples were again 
centrifuged at 6000 x g.  Buffer AW1 (500µl) was then added to each sample and 
centrifuged at 6000 x g for 1 minute.  The Mini columns were then place into clean 2ml 
collection tubes and the tubes containing the filtrate were discarded.  Buffer AW2 
(500µl) was added to the Mini columns and centrifuged at 20,000 x g for 3 minutes.  
The Mini columns were placed in clean 1.5ml micro-centrifuge tubes discarding the old 
collection tubes containing filtrate.  The QIAamp Mini columns were carefully opened 
and 60µl of Buffer AVE equilibrated to room temperature was added to each of them.  
They were left at room temperature for 1 minute then centrifuged at 6000 x g for 1 
minute.  Samples were then stored at -20°C. 
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 One-Step RT-PCR Kit  2.4
RT-PCR was carried out using Qiagen OneStep RT-PCR Kit (210210).  Briefly, a master 
mix was prepared including the following components per sample: 
DEPC treated H₂O      8.0µl 
5x QIAGEN OnStep RT-PCR Buffer    5.0µl 
dNTP mix       1.0µl 
5x Q-Solution       5.0µl 
Primer A       1.0µl 
Primer B       1.0µl 
QIAGEN OneStep RT-PCR Enzyme Mix    1.0µl 
Total RNA       2.0µl  
The master mix (23µl) was added to each tube along with the RNA sample (2µl) to give 
a total volume of 25µl and placed in VWR Thermocycler using the following program to 
amplify the products: 
60°C – 30 minutes 
95°C – 15 minutes 
94°C -   1 minute 
55°C –   1 minute  35 Cycles 
72°C –   1.5 minutes 
72°C - 10 minutes 
4°C   -  Pause 
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 Measurement of concentration and purity of RNA 2.5
Each RNA sample (2µl) was loaded onto a NanoDrop® ND-1000 spectrophotometer 
(Thermo Scientific UK) and a measurement was taken. A modification of the Beer-
Lambert equation was used to calculate sample concentrations:   
C = (A * Ɛ)/b  Absorbance x Wavelength/Pathlength in cm 
 were C is the nucleic acid concentration in ng/µl 
           A is the absorbance in AU (absorbance units) 
           Ɛ is the wavelength-dependent extinction coefficient in ng-cm/µl 
           b is the pathlength in cm 
Concentrations were calculated using the above described formula by the nanodrop 
software. 
The absorption at 260 nm and the (260 nm/280 nm) absorption ratio was measured as 
an indication of the purity of the RNA. A ratio ~2.0 was taken as the optimal “pure” 
value.   
 RNA Extraction – Trizol Method 2.6
Total RNA was extracted using the Trizol method.  Briefly, Trizol (Invitrogen 
13547901) (1ml) was added to faecal samples (2, 5 and 8) which were then 
homogenised in short bursts using PT2500E Polytron homogeniser (Kinematica) and 
incubated at room temperature for 5 minutes.  Chloroform (VWR 22706.326) (0.2ml) 
was added and the samples were shaken vigorously by hand for 15 seconds.  Samples 
were incubated at room temperature for 3 minutes and then centrifuged at a speed of 
12000 x g for 15 minutes at 4°C using Eppendorf Centrifuge 5415R.  The aqueous 
phase was transferred to a fresh Eppendorf tube.  RNA was precipitated by the addition 
of isopropanol (Fisher Scientific 1493415) (0.5ml); samples were incubated at room 
temperature for 10 minutes, and then centrifuged at 12000g for 10 minutes at 4°C.  
Supernatant was removed then 75%(v/v) Ethanol (VWR 20821.330) (1ml) was added 
and the sample was vortexed until the pellet dislodged from the tube.  The sample was 
then centrifuged at 7500 x g for 5 minutes at 4°C, the ethanol carefully removed and 
the pellet air dried for 15 minutes before being dissolved in RNAse-free water (Life 
Technologies AM9938) (1ml) and incubated at 65°C for 10 minutes. Samples were then 
stored at -20°C. 
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 Reverse Transcription 2.7
Reverse transcription was carried out using Promega ImProm-II™ Reverse 
Transcription System (Promega UK Ltd A3800).  Briefly, Total RNA (8µl), 10xRQ1 
buffer (1µl) and RQ1 DNase (1µl) were added to an RNase-free sterile tube and the 
samples were incubated at 37°C for 30 minutes.  RQ1 stop buffer (1µl) was added to 
each sample which was then incubated at 65°C for 10 minutes to inactivate the DNase.  
Samples were put on ice and DNase treated RNA (4µl) was then added to M3 primer 
(CAC ATT AGA GTC ATC TTC TA) (1µl) (the complement to the N gene of MHV) to make 
the cDNA and incubated at 70°C for 5 minutes.  A master mix containing the following 
reagents was made up (all reagents came with Reverse Transcription System): 
 
DEPC treated H₂O      7.3µl 
ImPromII 5× reaction buffer     4.0µl 
MgCl₂        1.2µl 
dNTP mix       1.0µl 
Ribonuclease Inhibitor      0.5µl 
ImProm II Reverse Transcriptase    1.0µl 
Master mix (15µl) was added to each tube giving a total volume of 20µl.  The samples 
were then incubated at: 
25°C for 5 minutes 
42°C for 1 hour 
70°C for 15 minutes 
Then stored at -20°C. 
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 First strand cDNA Positive Control 2.8
To check that the synthesis of first-strand cDNA had worked using the ImProm-II 
Reverse Transcription System kit a test run was carried out using a positive control. 
Kanamycin Positive Control RNA (1µg) was added (2µl of 1.2kb) to 1µl of Oligo(dT)₁₅ 
Primer (0.5µg/reaction) and 2µl of Nuclease-Free Water in a thin-walled dilution tube 
to give a final volume of 5µl.  The tube was then placed into a preheated 70°C heat 
block for 5 minutes.  It was then immediately chilled on ice for 5 minutes.  The tube 
was then spun for 10 seconds in a micro-centrifuge.  A reverse transcription reaction 
mix was made up including the following and added to the tube to make a final volume 
of 20µl: 
 
Nuclease-Free H₂O       7.3µl 
ImProm-II        4.0µl 
MgCl₂         1.2µl 
dNTPs         1.0µl 
Recombinant RNasin Ribonuclease Inhibitor    0.5µl 
ImProm-II Reverse Transcriptase     1.0µl 
Total Volume       15.0µl                  
 
 The mixture was then incubated for the following times on a heat block: 
 
Annealed 25°C – 5 minutes  
Extended 42°C – 60 minutes 
Inactivated 70°C – 15 minutes 
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The cDNA was then amplified by PCR by adding the above products to the following 
PCR mix and proceeded with thermal cycling on VWR Thermocycler: 
 
Nuclease-free H₂O      16.0µl 
10x Buffer          2.5µl 
MgCl₂           1.5µl 
dNTPs           0.5µl 
Forward Primer                1.0µl 
Reverse  Primer          1.0µl 
Taq DNA polymerase         0.25µl 
cDNA           1.0µl 
 
 
Thermocycler Program: 
94°C – 2minutes 
94°C – 1minute 
60°C – 1minutes  25 Cycles 
72°C – 2minutes 
72°C – 5minutes 
4°C   -  Pause 
 
 Measurement of concentration of DNA 2.9
cDNA samples (2l) were placed in the NanoDrop spectrophotometer and 
measurements taken as above.  The ratio of absorbance at 260nm and 280nm was used 
to assess the purity, with a value of ~1.8 being taken as optimal for DNA. 
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   Polymerase Chain Reaction 2.10
The following primers, which target regions within N protein of the MHV genome, were 
designed using Primer3 web version 4.0.0,(Koressaar T 2007; Untergrasser A 2012) 
and obtained from Eurofins MWG Operon.  The N protein sequence was input into the 
program, which then produce a number of possible primers that could be used (figure 
11) 
ATGTCTTTTGTTCCTGGGCAAGAAAATGCCGGTGGCAGAAGCTCCTCTGTAAACCGCGCTGGTAATGG 
AATCCTCAAGAAGACCACTTGGGCTGACCAAACCGAGCGTGGACCAAATAATCAAAATAGAGGCAGAA 
GGAATCAGCCAAAGCAGACTGCAACTACTCAACCCAACTCCGGGAGTGTGGTTCCCCATTACTCCTGG 
TTTTCTGGCATTACCCAGTTCCAAAAGGGAAAGGAGTTTCAGTTTGCAGAAGGACAAGGAGTGCCTAT 
TGCCAATGGAATCCCCGCTTCAGAGCAAAAGGGATATTGGTATAGACACAACCGCCGTTCTTTTAAAA 
CACCTGATGGGCAGCAGAAGCAATTACTGCCCAGATGGTATTTTTACTATCTTGGCACAGGGCCCCAT 
GCTGGAGCCAGTTATGGAGACAGCATTGAAGGTGTCTTCTGGGTTGCAAACAGCCAAGCGGACACCAA 
TACCCGCTCTGATATTGTCGAAAGGGACCCAAGCAGTCATGAGGCTATTCCTACTAGGTTTGCGCCCG 
GCACGGTATTGCCTCAGGGCTTTTATGTTGAAGGCTCTGGAAGGTCTGCACCTGCTAGCCGATCTGGT 
TCGCGGTCACAATCCCGTGGGCCAAATAATCGCGCTAGAAGCAGTTCCAACCAGCGCCAGCCTGCCTC 
TACTGTAAAACCTGATATGGCCGAAGAAATTGCTGCTCTTGTTTTGGCTAAGCTCGGTAAAGATGCCG 
GCCAGCCCAAGCAAGTAACGAAGCAAAGTGCCAAAGAAGTCAGGCAGAAAATTTTAAACAAGCCTCGC 
CAAAAGAGGACTCCAAACAAGCAGTGCCCAGTGCAGCAGTGTTTTGGAAAGAGAGGCCCCAATCAGAA 
TTTTGGAGGCTCTGAAATGTTAAAACTTGGAACTAGTGATCCACAGTTCCCCATTCTTGCAGAGTTGG 
CTCCAACAGTTGGTGCCTTCTTCTTTGGATCTAAATTAGAATTGGTCAAAAAGAATTCTGGTGGTGCT 
GATGAACCCACCAAAGATGTGTATGAGCTGCAATATTCAGGTGCAGTTAGATTTGATAGTACTCTACC 
TGGTTTTGAGACTATCATGAAAGTGTTGAATGAGAATTTGAATGCCTACCAGAAGGATGGTGGTGCAG 
ATGTGGTGAGCCCAAAGCCCCAAAGAAAAGGGCGTAGACAGGCTCAGGAAAAGAAAGATGAAGTAGAT 
AATGTAAGCGTTGCAAAGCCCAAAAGCTCTGTGCAGCGAAATGTAAGTAGAGAATTAACCCCAGAGGA 
TAGAAGTCTGTTGGCTCAGATCCTTGATGATGGCGTAGTGCCAGATGGGTTAGAAGATGACTCTAATG 
TGTAA 
Figure 11: Sequence of N gene including possible target primer sequences for amplification 
Primers Left 1forward and Right 1 reverse   Primers Left 2 forward and Right 2 reverse  
Primers Left3 forward and Right 3 reverse Primer left 4 forward 
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Table 4: New primers obtained from Primer3 web version 4.0.0 (Koressaar T 2007; Untergrasser A 2012) 
as the original primers used had high hairpin stability and unsuitable melting temperatures. 
Primer Start Length Melting 
Temp 
Sequence 
Left 1 2 21 58.97 TGTCTTTTGTTCCTGGGCAAG 
Left2 248 20 57.74 TTGCAGAAGGACAAGGAGTG 
Left3 754 20 58.77 CCCAAGCAAGTAACGAAGCA 
Left4 1233 19 59.07 CGTTGCAAAGCCCAAAAGC 
Right1 120 20 58.34 ATTATTTGGTCCACGCTCGG 
Right2 (unmodified) 625 20 60.04 ATTGTGACCGCGAACCAGAT 
Right2 (modified) 625 18 58.03 ATTGTGACCGCGAACCAG 
Right3 (unmodified) 1141 23 58.82 TCTGGTAGGCATTCAAATTCT
CA 
Right3 (modified) 1141 22 56.14 TCTGGTAGGCATTCAAATTCT
C 
 
The Left 1 and Right 3 primers were used as they targeted a large area at either end of 
the N gene and amplify a 1139bp DNA fragment, whereas the Left 2 and Right 2 pair 
targeted a smaller region in the middle of the N gene and amplify a 377bp DNA 
fragment.  The Right 3 and Right 2 primers were modified to contain a C or G at the 3’ 
in order to clamp the primer and prevent “breathing” of ends, with the expectation that 
this would increase priming efficiency.  DNA “breathing” occurs when ends do not stay 
annealed but fray or split apart (Lorenz 2012). For the Right 3 primer, this was 
achieved by omitting the 3’-terminal A and for Right 2 primer, both the 3’-terminal A 
and T were omitted.  The modified primers were used in this project. 
Each sample (1µl) was added to a Master Mix of H₂O (16.25µl), 10x Dream Taq Buffer  
(Thermo Scientific EP0702) (2.5µl), dNTPs (Invitrogen 1214460) (0.5µl), BSA (Sigma 
A9418-100G) (2.5µl)  forward and reverse primers (1µl) and Dream Taq (Thermo 
Scientific EP0702) DNA Polymerase (0.25µl), giving a total volume of 25µl.  Each 25µl 
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PCR reaction therefore included:  10x Dream Taq Buffer (20mM MgCl₂), 0.2mM dNTPs, 
400ng/µl BSA, 4µM primers and 50U/ml Dream Taq.  
Amplification was performed on a VWR Thermocycler with an initial denaturation of 
94°C for 3 minutes then 35 cycles of 30 seconds denaturation at 94°C, annealing at 
54°C for Left 1 and Right 3, and 56°c for Left and Right 2, for 30 seconds, then primer 
extension at 72°C for 1 minute.  The extension of the last cycle was continued for 10 
minutes at 72°C.   
 Agarose  gel electrophoresis 2.11
The resulting amplified DNA product was detected by electrophoresis run on a 1.5% 
agarose gel. UltraPure™ Agarose (1.5gm) (Invitrogen 16500-500) and 100ml 1× TE 
Buffer (100ml) were heated for 1 minute and then 3µl Sybr® Safe DNA gel stain 
(Invitrogen S33102) was added before casting the gel. 2.5µl dye was then added to 
each 25µl sample, 10µl of which were then pipetted into a gel slot. A 1kb GeneRuler 
DNA ladder (Thermo Scientific #SM0311) was also added to the gel to confirm the 
correct band sizes. Electrophoresis was for 1 hour at 100volts, after which the nucleic 
acids were visualised by UV illumination using a Syngene U:Genius 3 illuminator. 
 Taqman Analysis 2.12
Newly extracted and Reverse Transcribed samples were diluted to 1:80 i.e. 2µl of each 
cDNA sample was added to 158µl of ddH₂O to give a total volume of 160µl.  A master 
mix of the following was made up in triplicate for each sample: 
18s Primer and Probe (1256325 Applied Biosystems)    1µl 
 Hmox1 gene Primer and Probe (1170383 Applied Biosystems)  1µl 
Taqman Gene expression Master Mix (4369016 Applied Biosystmes) 10µl 
12µl of master mix was added in triplicate to a 96well plate plus 8µl of diluted cDNA for 
each sample. 
This was then run of Taqman Real Time PCR system using 7500 system software. 
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 “Positive control” DNA 2.13
A synthetic cDNA of the N gene, based on the database sequence for the A59 strain of 
MHV was obtained from Life Technologies to be used as a positive control (Figure 12).  
It was assembled from a number of overlapping synthetic oligonucleotides and 
inserted into a plasmid for cloning and extraction. 
 
 
 DNA transformation  2.14
The plasmid DNA was transformed into 10-beta E. coli bacteria (New England BioLabs 
C3019H).    
Briefly, 1µl of plasmid DNA was added to 50µl competent cell mixture (10-Beta).  The 
tube was flicked 4-5 times to mix the cells and DNA.  The mixture was then placed on 
ice for 30 minutes.  It was then placed in an Eppendorf Thermomixer Compact at a 
temperature of 42°C for 30 seconds in order to open the cells by heatshock.  The 
sample was then placed on ice for 2 minutes in order to close the cells.  950µl of SOC 
medium was then added and it was placed in a shaking incubator at 37°C for 60 
N-MHVA59Gene name:
Designation:
Gene size:
E.coli K12 (dam+ dcm+ tonA rec-)
1440 bp
Vector backbone: pMA-RQ (ampR)
Cloning sites: SfiI / SfiI
Quantity: ~5 µg Plasmid DNA
Note: Please dissolve lyophilized DNA in 50 µl distilled water or
10 mM Tris-HCl (pH 8.0). We recommend sequence
verification after each transformation step.
Date: 22  May 2013
GeneArt AG    www.lifetechnologies.com    GeneArtSupport@lifetech.com
Anja Philipps
Quality control
Quality Assurance Documentation: 13AAN7PP
Ref. No.: 1340439
The synthetic gene N-MHVA59 was assembled from synthetic oligonuc leotides
and/or PCR  products. The fragment was cloned into pMA-RQ (ampR) using  SfiI
and SfiI  cloning sites. The plasmid DNA was purified from transf ormed bacteria
and concentration  determined by UV spectroscopy. The final const ruct was
verified by sequencing.  The sequence congruence within the used restriction sites
was 100%. See  the accompanying data sheets for sequences and fin d the original
ABI trace files as  well as the assembled sequences electronicall y on disk.
5 µg of the plasmid preparation were lyophilized for shipping.
Plasmid DNA Description:
Plasmid Map:
Figure 12: Description of Synthetic DNA obtained from Life Technologies 
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minutes.  Cell mixture (50-100µl) was then spread on LB agar plates containing 
100µg/ml of LB-ampicillin and incubated overnight at 37°C in an incubator.  Two 
colonies were then grown in 5ml of LB-ampicillin in a 37°C incubator with 250rpm 
shaking for 8 hours.  Then 200µl of the 5ml culture was transferred to 100ml LB-
ampicillin and incubated overnight at 37°C with 250rpm shaking. 
The DNA was then extracted from the 100ml overnight culture and purified using a 
Qiagen Midi Kit (13343) as per the manufacturer’s instructions.  
  “Negative control” DNA 2.15
For some experiments, faecal samples were collected from C57BL/6J mice held in 
another resource unit in the University, in which MHV has never been detected. These 
were shipped to the laboratory at ambient temperature and then processed 
immediately for RNA extraction. 
Distilled water was also used as a negative control. 
 Serological testing 2.16
After animals were killed, a single spot of blood was blotted onto “OptiSpot” paper 
(supplied by IDEXX). After drying, the samples were stored at 4°C before being shipped 
to IDEXX Laboratories for MHV serology testing. 
 
38 
 
3 Results 
 Trizol method and RT-PCR Vs RNA mini kit and one-step 3.1
PCR 
The extraction and PCR were tried two different ways.  The first way was using a   
“Mini Kit” designed for RNA extraction and then a one-tube process for reverse 
transcription and PCR amplification.  The second was RNA extraction using the 
standard Trizol method, which would be followed by reverse transcription and PCR. 
Gross RNA yields are compared in figures 13 and 14. The Trizol method proved to give 
a higher yield, however, the differences in yield is likely representative of extracting 
RNA from whole pellets (Trizol) vs. filtered supernatants (mini kit). In addition, no 
positive results were obtained after three attempts with the one-tube PCR reaction 
after use of the Mini Kit. The one-tube PCR reaction was not tried with the Trizol 
method and vice versa.  Trizol method of RNA extraction, followed by separate reverse 
transcription and PCR steps was adopted as the standard procedure in further work as 
this gave positive results after the first attempt. 
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Figure 13: RNA yield using viral mini kit.  Amount of RNA (ng/µl) in samples containing 2, 5 
and 8 faecal pellets. 
Data represents mean ± standard deviation, N=3 determinations 
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 RNA yield from faecal pellets 3.2
Fresh faecal samples were collected in different numbers from randomly chosen mice 
in the general population of the MSRU and RNA was extracted using the Trizol method.  
RNA yield versus number of pellets was compared.  RNA yield increased in a linear 
fashion from one to three pellets, however, any further increase in pellet numbers did 
not increase RNA yield significantly (Figure 15), indicating a saturation of the 
extraction method at the quantities of reagents used.  Therefore, three pellets were 
used in all future work, as this gave the maximum RNA yield within the linear range.  
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Figure 13: RNA yield using Trizol extraction.  Amount of RNA (ng/µl) in samples containing 
2, 5 and 8 faecal pellets. 
Data represents mean ± standard deviation, N=3 determinations 
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Figure 14: RNA yield of faecal pellets.  Amount of ng of RNA per µl of sample 
for 1-6 faecal pellets. 
Data represents mean ± standard deviation, N=3 determinations 
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 Tests for amplification 3.3
It was important to verify that the extracted RNA could indeed be reverse-transcribed 
into cDNA and that this could then yield a PCR amplification product. Two approaches 
were used, both depending on the likely presence in faecal material of cellular debris 
from the gastrointestinal tract. 
3.3.1 Analysis of haem oxygenase-1 expression 
Faecal samples were collected from mice that were involved in a study of haem 
oxygenase-1 (HO-1) expression - “Evidence that the capacity of nongenotoxic 
carcinogens to induce oxidative stress is subject to marked variability”(Henderson, 
Cameron et al.), and processed by the standard methods. A Taqman analysis was 
performed on samples from control animals and mice in which HO-1 expression was 
expected to be elevated (Figure 16). A significant increase in this signal was indeed 
detected. 
 
 
 
 
3.3.2 Actin expression 
Reverse transcription and PCR reactions were carried out, targeting the mRNA for β-
Actin, a ubiquitous protein that is present in mammalian cells.  A PCR product of the 
expected size was indeed obtained (Figure 17). 
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Figure 15:  Taqman test was performed using HO-1.  Control – Haemoxygenase-1 Dual 
Reporter (HOD) mouse treated with corn oil and Dichlorobenzene (DCB) treated HOD mouse. 
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 Synthetic Positive Control 3.4
Synthetic cDNA of N-MHVA59 gene was obtained from Life Technologies to be used as 
a positive control (Figure 12).    After transformation the plasmid DNA stock was 
diluted to 50ng/µl, 5ng/µl, 0.5ng/µl, 0.05ng/µl and 0.005ng/µl and used as template 
DNA for PCR reactions using the primer pairs:  P1forward and P3 reverse and P2 
forward and reverse (modified primers).  An example of the PCR products formed is 
shown in figures 18 and 19.  These bands correspond to the predicted molecular 
weights for each primer pair. 
 
Figure 17: Agarose gel electrophoresis of PCR product of diluted plasmid DNA stock using primers P2 
forward and reverse. 
M = DNA marker ladder, 1-5 = diluted DNA 5ng/µl, 5ng/µl, 0.5ng/µl, 0.05ng/µl, 0.005ng/µl 
M     1    2     -
154bp
250bp
250bp
500bp
750bp
1,000bp
377bp
 M   1     2     3     4     5
Figure 16: Results of RT-PCR to detect β-actin in a 
faecal sample.  M – Ladder, 1 – Non-diluted cDNA, 
2 – cDNA diluted 1:10, 3 – Negative Control (H₂O) 
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 First-strand cDNA Positive Control 3.5
To check that the synthesis of first-strand cDNA had worked using the ImProm-II 
Reverse Transcription System kit a test run was carried out using a positive control 
(Figure 20).  This positive control was included with the ImProm-II kit and the reaction 
was run as per the manufacturer’s instructions (see sections 2.8 of materials and 
methods) 
 
 
 
M     1
500
250
323bp
Figure 19: 1.2kb Kanamycin Positive Control                                   
M= DNA marker ladder, 1=Positive Control 
1,139bp
250bp
500bp
750bp
 1,000bp
M    1     2     3     4     5
Figure 18: Agarose gel electrophoresis of PCR product of diluted plasmid DNA stock using primers P1 
forward and P3 reverse. 
M = DNA marker ladder, 1-5 = diluted DNA 5ng/µl, 5ng/µl, 0.5ng/µl, 0.05ng/µl, 0.005ng/µl 
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 Amplification of MHV N-gene fragment from extracted RNA 3.6
Faecal samples were collected from 10 random weanling mice in various rooms within 
the general population of the animal unit. All animals were between 3-21 days after 
weaning, at a time when maternal passive immunity was likely to have disappeared.  
Figure 21 shows the results of one of the groups of mice samples were collected from, 
using primers Left 1 (P1) and Right 3 (P3).  Three mice tested positive for MHV. 
 
 
 
 
 
 
A PCR was then run again on the positive samples (3, 4, and 7) using Primer 2 forward 
and 2 reverse.  These also tested positive for MHV (Figure 22). 
M   1    2    3     4    5    6    7     8     9    10    -    +
1139bp
 250bp
              500bp
              750bp
           1,000bp
Figure 20: RT-PCR amplification of MHV N gene from fresh faecal samples 
RNA was prepared from fresh faecal samples from 10 random weanling mice in MSRU, reverse transcribed 
and PCR for the MHV N gene with Primers P1 Forward and P3 Reverse carried out and run.   Agarose gel 
electrophoresis was run as detailed in Materials and Methods.  
 M – DNA marker ladder.  Lanes 1,2,5,6,8,9,10 – negative results.  Lanes 3,4,7 – positive results with the 
correct band of 1139bp. 
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Figure 21: PCR amplification of MHV gene using primers P2 forward and P2 reverse L – DNA Marker 
Ladder.  Lanes 3, 4, and 7 showing positive results with correct band of 377bp. 
 Sequencing of Positive Result 3.7
The PCR product of one of the positive results (sample 3 above) was sent for 
sequencing to the Medical School Core DNA Sequencing Facility analysis, using primer 
P1-fwd.   Results are shown in figure 23, and demonstrate a sequence identity of 88% 
with the N-gene as recorded in the standard sequence databases. The PCR product was 
clearly highly related to the viral sequence (note that an exhaustive and repeated 
comparison was not performed, so sequencing errors cannot be ruled out as being 
responsible for being some or all of the differences). 
 
N-Gene 132   CAGAAGGAATCAGCCAAAGCAGACTGCAACTACTCAACCCAACTCCGGGAGTGTGGTTC  191 
             ||| || || |||||||||||  |||||||||||||  ||||| |||||||||||||||| 
MS1    86    CAGGAGAAACCAGCCAAAGCAKWCTGCAACTACTCAGTCCAACCCCGGGAGTGTGGTTCC 145 
 
N-Gene 192   CCATTACTCCTGGTTTTCTGGCATTACCCAGTTCCAAAAGGGAAAGGAGTTTCAGTTTGC 251 
             | ||||||| |||||||| ||||||||||| ||||| | ||||||| | || |||||||| 
MS1    146   CTATTACTCTTGGTTTTCGGGCATTACCCAATTCCAGAGGGGAAAGCAATTCCAGTTTGC 205 
 
N-Gene 252   AGAAGGACAAGGAGTGCCTATTGCCAATGGAATCCCCGCTTCAGAGCAAAAGGGATATTG 311 
             |||||||||||||||||||||||||||||||||||| ||  | ||||||||||||||||| 
MS1    206   AGAAGGACAAGGAGTGCCTATTGCCAATGGAATCCCAGCCACTGAGCAAAAGGGATATTG 265 
 
N-Gene 312   GTATAGACACAACCGCCGTTCTTTTAAAACACCTGATGGGCA-GCAGAAGCAATTACTGC 370 
             || |||||||||||| ||||||||||||||||||||||||||  || || ||| |  | | 
MS1    266   GTTTAGACACAACCGGCGTTCTTTTAAAACACCTGATGGGCAAACA-AAACAACTTTTAC 324 
 
N-Gene 371   CCAGATGGTATTTTTACTATCTTGGCACAGGGCCCCATGCTGGAGCCAGTTATGGAGACA 430 
             || | ||||||||||||||||| ||||| || ||| ||||    |||   ||||| ||   
MS1    325   CCCGCTGGTATTTTTACTATCTCGGCACTGGACCCTATGCCTCTGCCGAATATGGCGATG 384 
 
N-Gene 431   GCATTGAAGGTGTCTTCTGGGTTG-CAAACAGCCAAGCGGACACCAATACCCGCT-CTGA 488 
              ||| ||||| ||||  ||||| | |||  || || || ||||  || ||| ||| | || 
MS1    385   ACATCGAAGGAGTCTGTTGGGTCGCCAATAAG-CAGGCTGACATTAAGACC-GCTGCCGA 442 
 
N-Gene 489   TATTGTCGAAAGGGACCCAAGCAGTCATGAGGCTATTCCTACTAGGTTTGCGCCCGGCAC 548 
             |||||  || ||||||||||||||||||||||||||||||||||||||||||||||| || 
MS1    443   TATTGCTGAGAGGGACCCAAGCAGTCATGAGGCTATTCCTACTAGGTTTGCGCCCGGTAC 502 
 
Figure 22 Comparison of partial sequence (380bp) of N gene of MHV genomic RNA from a positive mouse 
sample (MS1) 
  M     3       4       7       -         +
377bp
              250bp
            500bp
           750bp
     1,000bp
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 Serial dilution of positive sample 3.8
To assess the sensitivity of the RT-PCR, one of the positive mouse samples was serially 
diluted 1:2 with water.  By the fourth dilution (Figure 24, lane 5) no product can be 
seen.  This confirms RT-PCR should be sensitive enough to detect the virus over some 
range of concentrations in the samples.  It does not, however, determine the limit of 
sensitivity of the assay. 
 
   
Figure 23: Serial dilution of a positive sample.  L – DNA marker.  Lane 1 – no dilution.  Lanes 2 – 5: 
serial dilution 1:2 with H₂O 
 
 Nested PCR 3.9
It was first thought that a nested PCR would be required as this had been used in 
previous studies with good results.  As the virus was being collected from faecal 
samples it was assumed that any virus extracted would be limited to very small 
amounts and a nested PCR is more sensitive.  Primers Left 1 and Right 3 were used in 
the first round of PCR as this targeted a large area of the N gene, and primers Left 2 and 
right 2 were used in the second round of PCR as this targeted a smaller area within the 
large area.  Initially results were good with the second round of PCR giving a positive 
result when the first round did not.  However, after running a few of these PCRs there 
were signs of contamination, with many of the negative control (water) samples giving 
a positive result also. It was concluded that the likely efficiency of PCR would have been 
improved greatly since the first reports of its use in detecting MHV and that the added 
sensitivity of a nested approach might now be detecting and irreducible “background” 
(see below). Therefore, the further use of nested PCR was abandoned. 
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 Contamination issues 3.10
At several points during the project, serious contamination issues were encountered. 
There was contamination caused by the plasmid positive control which was combated, 
by using this highly concentrated source of viral sequences as rarely as possible, and 
handling it in strict isolation in the fume hood. All master mix components were also 
aliquoted into single reaction amounts in order to reduce cross contamination.  This 
worked well eliminating contamination.  Figures 25 and 26 show examples of gels that 
show contamination. 
 
 
 
 
 
 
 
 
        M   1    2     3    4    5    6    7    8    9  10    M  11  12  13 14 15 16  17 18 19  20   +    +   -
250bp
500bp
750bp
 1,000bp
377bp
Figure 24: Example of contaminated samples of mouse 5 using primers P2 forward and reverse.  All 
samples and negative control show contamination. 
M= DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MRSU, second + = synthetic positive control, - = negative control 
Figure 25: Example of contaminated samples of mouse 5 using primers P1 forward and P3 reverse.  All 
samples and negative control show contamination. 
M= DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MRSU, second + = synthetic positive control, - = negative control 
 M   1   2    3    4    5    6   7    8    9   10   11   12  13 14 15  M   16  17   18   19   20    +     +     -
1,000bp
750bp
500bp
250bp
1,139bp
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 Optimisation of the PCRs 3.11
 
Gradient PCRs were performed on a known positive sample using both primer pairs 
(P1P3 and P2 forward and reverse) to determine the optimal annealing temperatures.  
For Primers P1 and P3 a range of between 48.6°C and 57.2°C was suitable, and for 
primers P2  forward and reverse a range of 48.6°C and 60.9°C gave the best results 
(figure 27 and 28).  The number of cycles was also varied (30 and 35 cycles), however 
this made no difference to the outcomes of PCRs (figures 29 and 30). 
 
 
 
  
  
1,000bp
750bp
500bp
250bp
1,139bp
 M   1    2    3    4    5   6   7   8   9   10
Figure 26:  Gradient PCR performed on a known positive sample 
using Primers P1 and P3 
M=DNA ladder, 1=48.6°C, 2=49.9°C, 3=51.2°C, 4=54.0°C, 5=57.2°C, 
6=60.9°C, 7=64.0°, 8=66.5°C, 9=68.2°C 10=69.5°C 
1,000bp
750bp
500bp
250bp
377bp
   M   1     2     3     4    5      6     7     8     9    10
Figure 27:  Gradient PCR performed on a known positive sample 
using Primers P2 forward and reverse 
M=DNA ladder, 1=48.6°C, 2=49.9°C, 3=51.2°C, 4=54.0°C, 5=57.2°C, 
6=60.9°C, 7=64.0°, 8=66.5°C, 9=68.2°C 10=69.5°C 
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1,000bp
750bp
500bp
250bp
1,139bp
   M   1     -     +          M    1    -    +
       35 Cycles               30 Cycles
1,000bp
750bp
500bp
250bp
377bp
   M   1     -     +          M    1    -    +
       35 Cycles               30Cycles
Figure 28:  PCRs performed with Primers P1 and P3 using two different numbers of cycles 
M = DNA ladder, 1 = Known positive sample, - = Negative control (H₂O), + = Plasmid positive 
control 
Figure 29:  PCRs performed with Primers P2 forward and reverse using two different 
numbers of cycles 
M = DNA ladder, 1 = Known positive sample, - = Negative control (H₂O), + = Plasmid positive 
control 
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 MHV detection in animals housed in the MSRU, from their 3.12
arrival 
RT-PCRs were performed on samples that were collected daily for 20 days (excluding 
weekends) from 5 male and 5 female 6-8 week old mice that were obtained from 
Charles River Laboratories (UK) Ltd, to determine if they had contracted MHV and for 
how long.  Faecal collection started the day after they arrived. 
Mouse 1 
 
 
 
 
 
 
 
 M    1     2    3    4     5     6     7    8      9   10    11   12  13  14   15   16  17   18  19  20   +   +  -
1,000bp
750bp
500bp
250bp
377bp
 M   1     2    3    4    5    6    7    8    9  10  11  12 13  14  15 16  M   17  18  19 20  +   +   -
1,000bp
750bp
500bp
250bp
1,139bp
Figure 30: Agarose gel electrophoresis of total RNA and RT PCR product of mouse 1 (male) using Primers 
P2 forward and reverse.   
M= DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of know 
nMHV positive mouse in MRSU, second + = synthetic positive control, - = negative control 
No positive results 
Figure 31: Agarose gel electrophoresis of total RNA and RT PCR product of mouse 1 (male) using Primers 
P1 forward and P3 reverse.   
M = DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MRSU, second + = synthetic positive control, - = negative control. 
No positive results 
50 
 
Mouse 2 
 
 
 
 
 
 
 
 
 
 M   1     2    3    4    5    6    7    8    9  10  11  12 13  14  15 16   17  18  19 20  +   +     -
1,000bp
750bp
500bp
250bp
1,139bp
M 1   2   3   4   5  6   7   8   9  10 11 12 13 14 15 16 17 18 19 20  +  +  -
250bp
500bp
750bp
1,000bp
Figure 32: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 2 (male) using 
primers P2 forward and reverse. 
M= DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MRSU, second + = synthetic positive control, - = negative control 
No positive results 
 
 
 
 
Figure 33: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 2 (male) using 
primers P1 forward and P3 reverse. 
M= DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MRSU, second + = synthetic positive control, - = negative control 
No positive results 
 
 
 
377bp 
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Mouse 3 
 
 
 
 
 
 
 
 
 
 
 
 
250bp
500bp
750bp
1,000bp
M  1   2    3  4   5  6     7   8   9 10  11 12 13 14 15 16 17 18 19 20 +  +   -
Figure 34: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 3 (male) using 
primers P2 forward and reverse. 
M= DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MRSU, second + = synthetic positive control, - = negative control 
No positive results 
 
 
250bp
500bp
750bp
1,000bp
M   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17 18 19 20 +   +    -
 
M= DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MRSU, second + = synthetic positive control, - = negative control 
No positive results 
 
 
Figure 35: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 3 (male) using 
primers P1 forward and P3 reverse. 
377bp 
 
1,139bp 
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Mouse 4 
 
 
Figure 36: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 4 (male) using 
primers P2 forward and reverse. 
M= DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MRSU, second + = synthetic positive control, - = negative control 
No positive results 
 
 
 
 
 
 
 
250bp
500bp
750bp
1,000bp
M  1 2 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17 18 19 20 +   +    -
377bp 
  M   1    2    3    4    5    6    7   8    9   10  11 12 13 14 15 16 17 18  19  20  +    +    -
250bp
500bp
750bp
1,000bp 1,139bp
Figure 37: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 4 (male) using 
primers P1 forward and P3 reverse. 
M = DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
  M   1   2    3    4    5     6     7    8    9   10  11  12 13  14 15  16 17  18  19  20  +    +    -
250bp
500bp
750bp
1,000bp
377bp
Figure 38: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 5 (male) using 
primers P2 forward and reverse. 
M = DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
  M   1   2    3    4    5     6     7    8    9   10  11  12 13  14 15  16 17  18  19  20  +     +    -
250bp
500bp
750bp
1,000bp 1,139bp
Figure 39: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 5 (male) using 
primers P1 forward and P3 reverse. 
M = DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 6 
 
 
 
 
 
 
 
 
 
 
 
 
  M   1   2    3    4    5     6     7    8    9   10  11  12 13  14 15  16 17  18  19  20  +     +    -
250bp
500bp
750bp
1,000bp
377bp
Figure 40: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 6 (female) using 
primers P2 forward and reverse. 
M = DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
  M   1   2    3    4    5     6     7    8    9   10  11  12 13  14 15  16 17  18  19  20   +    +    -
250bp
500bp
750bp
1,000bp
1,139bp
Figure 41: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 6 (female) using 
primers P1 forward and P3 reverse. 
M = DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
  M   1   2    3    4    5     6     7    8    9   10   11  12 13  14 15  16 17  18  19  20   +    +    -
250bp
500bp
750bp
1,000bp
377bp
Figure 42: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 7 (female) using 
primers P2 forward and reverse. 
M = DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
  M   1   2    3    4    5     6     7    8    9   10   11  12 13  14 15  16 17  18  19  20   +    +    -
250bp
500bp
750bp
1,000bp
1.139bp
Figure 43: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 7 (female) using 
primers P1 forward and P3 reverse. 
M = DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
250bp
500bp
750bp
1,000bp
  M    1     2     3    4     5     6     7    8     9    10    11  12  13   14  15  16  17  18   19  20    +     +   -
1,139b
M  1   2   3   4   5   6   7   8   9  10   11  12  13 14 15 16 17 18 19 20 + +   -
377bp
250bp
500bp
750bp
 1,000bp
Figure 44: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 8 (female) using 
primers P2 forward and reverse. 
M = DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
Figure 45: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 8 (female) using 
Primers P1 forward and P3 reverse. 
M = DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
M  1   2  3  4   5   6  7   8  9 10  11  12  13 14 15 16 17 18 19 20 + +   -
377bp250bp
500bp
750bp
 1,000bp
Figure 46: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 9 (female) using 
Primers P2 forward and reverse. 
M = DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
M  1   2  3  4   5   6  7   8  9 10  11  12  13 14 15 16 17 18 19 20  +  +   -
1,139bp
250bp
500bp
750bp
 1,000bp
Figure 47: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 9 (female) using 
Primers P1 forward and P3 reverse. 
M = DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 10 
 
 
 
 
 
 
 
 
 
 
 
 
M  1   2  3  4   5   6  7   8  9 10  11  12  13 14 15 16 17 18 19 20  +  +   -
377bp
250bp
500bp
750bp
 1,000bp
Figure 48: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 10 (female) using 
primers P2 forward and reverse. 
M = DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
M  1   2  3  4   5   6  7   8  9 10  11  12  13 14 15 16 17 18 19 20  +  +   -
1,139bp
250bp
500bp
750bp
 1,000bp
Figure 49: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 10 (female) using 
primers P1 forward and P3 reverse. 
M = DNA marker ladder, 1-20 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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In many cases, these experiments were repeated several times, with the same results 
being obtained; no reliable evidence of viral shedding was seen during the 30-day 
period after introduction of these animals into the MSRU.  Table 5 below shows a 
summary of results of screening of animal introduced into the MSRU. 
 
Table 5: Results of all screening performed on animals introduced into MSRU 
-  = Negative result of PCR test 
Mouse Number MHV PCR No. of times 
PCR 
repeated 
1 - 7 
2 - 5 
3 - 1 
4 - 1 
5 - 2 
6 - 1 
7 - 3 
8 - 1 
9 - 1 
10 - 1 
 
 MHV detection in animals born in the MSRU 3.13
Three breeding pairs were then set up from randomly chosen animals from the 
introduced cohort. Litters were weaned at 21 days after birth and faecal sampling from 
the offspring conducted daily from 3 days after weaning (excluding weekends) for 22 
days to determine if they had contracted MHV and for how long. 
 
 
 
 
 
60 
 
 
Mouse 1 (weanling) 
 
 
 
 
 
 
 
 
Mouse 2 (weanling) 
 
 
 
 
 
 1,000bp
750bp
500bp
250bp
1,139bp
M   1   2     3     4    5    6    7    8    9   10  11 12 13  14 15 16  17 18 19     M   20  21  22    +     +   -
Figure 51: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 1 (weanling) using 
primers P1 forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
 1,000bp
750bp
500bp
250bp
1,139bp
M  1   2    3    4     5     6     7    8     9   10  11 12      M  13  14  15    16  17   18   19    20  21  22     +     +    -
377bp
Figure 50: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 1 (weanling) using 
primers P2 forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 2 (weanling) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1,000bp
750bp
500bp
250bp
M     1    2    3    4     5     6     7    8     9   10   11  12  13  14  15  16   M  17  18  19  20  21  22   +    +   -
377bp
Figure 52: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 2 (weanling) using 
primers P2 forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
One positive result on day 6 
 1,000bp
750bp
500bp
250bp
1,139bp
M    1    2     3    4     5     6     7    8    9   10   11  12   13  14  15  16  M  17   18   19    20  21  22  +   +    -
Figure 53: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 2 (weanling) using 
primers P1 forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
One positive result on day 6 
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Mouse 3 (weanling) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   M    1    2    3     4    5     6      7    8     9    10  11  12  13   14  15   16     17  18   19  20  21  22   +   +   -
250bp
500bp
750bp
 1,000bp
377bp
Figure 54: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 3 (weanling) using 
primers P2 forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
One positive result on day 6 
   M    1    2    3     4    5     6      7    8     9    10  11  12  13   14  15   16    M  17  18   19  20  21  22   +   +   -
1,139bp
250bp
500bp
750bp
 1,000bp
Figure 55: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 3 (weanling) using 
primers P1 forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 4 (weanling) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 M   1    2    3    4    5    6    7   8    9  10  11  12 13  14  15 16 17   M   18   19  20    21  22   +   +     -
1,000bp
750bp
500bp
250bp
1,139bp
M  1    2     3    4    5    6   7   8   9  10  11  12  13  14  15  16 17 M    18   19   20   21   22    +   +   -
250bp
500bp
750bp
 1,000bp
377bp
Figure 56: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 4 (weanling) using 
primers P2 forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
12 positive results from day 2 - 12 and day 22 
Figure 57: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 4 using primers P1 
forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
5 positive results from day 2 – 6 and day 22 
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Mouse 5 (weanling) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M  1     2     3     4     5     6     7     8     9    10  11  12  13   14  15   16    M   17   18   19   20   21   22   +   +   -
250bp
500bp
750bp
 1,000bp
377bp
Figure 58: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 5 using primers P2 
forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
15 positive results from day 1 - 15 
M  1     2     3     4     5     6     7     8     9    10  11  12  13   14  15   16  M   17   18   19   20   21   22   +   +   -
1,139bp
250bp
500bp
750bp
 1,000bp
Figure 59: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 5 using primers P1 
forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 6 (weanling) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M   1     2     3     4     5     6     7     8     9    10  11  12  13   14  15   16    M   17   18   19   20   21   22   +   +   -
250bp
500bp
750bp
 1,000bp
377bp
Figure 60: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 6 using primers P2 
forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
15 positive results from day 1 - 15 
M   1     2     3     4     5     6     7     8     9    10  11  12  13   14  15   16    M   17   18   19   20   21   22   +   +   -
1,139bp
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Figure 61: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 6 using primers P1 
forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 7 (weanling) 
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Figure 62: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 7 using primers P2 
forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
13 positive results from day 2 – 4, day 6 and day 8 - 16 
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Figure 63: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 7 using primers P1 
forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
9 positive results on day 2,6, 8-10 and 12-15 
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Mouse 8 (weanling) 
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Figure 64: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 8 using primers P2 
forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
10 positive results from day 7 - 16 
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Figure 65: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 8 using primers P1 
forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
12 positive results from day 8 - 19 
68 
 
Mouse 9 (weanling) 
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Figure 66: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 9 using primers P2 
forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
14 positive results from days 8 – 10, 12 – 18 and 20 - 22 
Figure 67: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 9 using primers P1 
forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
6 positive results from days 8 – 10, 12, 13 and 17 
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Mouse 10 (weanling) 
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Figure 68: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 10 using primers P2 
forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
Positive results from day 1 – 6, 11 and 12, 16 and 17 
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Figure 69: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 10 using primers P1 
forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 11 (weanling) 
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Figure 70: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 11 using primers P2 
forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
Positive results from day 2 - 4 
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Figure 71: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 11 using primers P1 
forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 12 (weanling) 
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Figure 72: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 12 using primers P2 
forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Figure 73: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 12 using primers P1 
forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 13 (weanling) 
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Figure 74: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 13 using primers P2 
forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Figure 75:  Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 13 using primers P1 
forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 14 (weanling)  
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Figure 76: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 14 using primers P2 
forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
Positive result on day 4 and 12 
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Figure 77: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 14 using primers P1 
forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 15 (weanling) 
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Figure 78: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 15 using primers P2 
forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
Positive result on day 1 and 10 
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Figure 79: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 15 using primers P1 
forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Mouse 16 (weanling) 
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Figure 80: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 16 using primers P2 
forward and reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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Figure 81: Agarose gel electrophoresis of total RNA and RT-PCR product of Mouse 16 using primers P1 
forward and P3 reverse. 
M = DNA marker ladder, 1-22 = days faecal samples were taken from mouse, first + = sample of known 
MHV positive mouse in MSRU, second + = synthetic positive control, - = negative control 
No positive results 
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In summary, a range of different patterns were observed: 
 Some animals never showed evidence of having become infected (Mouse 1, 12, 
13 and 16). 
 Some animals gave a reproducible viral signal on one or two days at some point 
during the observation period (Mouse 2, 3, 11, 14 and 15). 
 Some animals appeared to be shedding virus over a prolonged period of time, 
including in some cases the last day of observation (Mouse 4, 5, 6, 7, 8, 9, 10). 
 In some animals, there appeared to be more than one cycle of infection (Mouse 
4, 7, 9, 10, 14 and 15). 
 
In some of the mice (44%), one PCR gave a positive result and the other was apparently 
negative.  In every case, the positive result was obtained when the smaller PCR 
fragment was being amplified.  It is thus possible that amplification was more efficient 
in this reaction.  In general, the smaller PCR worked well, with the band clearly distinct 
from the dye front on the gel (in which the primers are expected to run) and was 
therefore considered reliable.  It is clear that there is not one simple pattern of 
infection.  Table 6 shows the pattern of infection of 12 of the weanling mice, with 50% 
of these mice testing positive for both PCR and serology. 
 
Table 6:  Pattern of infection of 12 weanling mice 
 + PCR - PCR 
+ Serology 6 2 
- Serology 3 1 
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 Comparison of serology and PCR data 3.14
Blood samples were taken from 22 of the 26 mice and sent for serology testing to 
compare results with the RT-PCR to see which animals had in fact become infected 
with MHV. 
Table 7: Results of Opti-Spot Serology Testing of 22 mice.  
+ = positive, - = negative, W = weak positive, N = normal IgG 
Mouse Number Mouse IgG MHV Serology MHV PCR Mouse selected 
as breeder 
1 N + -  
2 N W -  
3 N + -  
4 N - - x 
5 N W - x 
6 N + -  
7 N - -  
8 N + -  
9 N + - x 
10 N + - x 
1 (weanling) N + - x 
2 (weanling) N +  + x 
3 (weanling) Not tested Not tested Faint band x 
4 (weanling) N + + x 
5 (weanling) N + + x 
6 (weanling) Not tested Not tested + x 
7 (weanling) N + + x 
8 (weanling) N + + x 
9 (weanling) Not tested Not tested + x 
10 (weanling) N - + x 
11 (weanling) N - Faint band x 
12 (weanling) Not tested Not tested - x 
13 (weanling) N + - x 
14 (weanling) N + Faint bands x 
15 (weanling) N - + x 
16 (weanling) N - - x 
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For animals 1-10 (those introduced into the MSRU), a serological positive was obtained 
in most, but not all, cases, even though no viral shedding had been detected in any of 
them.  Note that the blood sampling took place several months after the experiment, so 
it is possible that these animals only became infected after the faecal sampling had 
stopped. 
For the 12 sampled weanlings, eight were unequivocally positive by serology and four 
negative.  Six animals were positive for both serology and the MHV PCR (weanlings 2, 
4, 5, 7, 8 and 14) and one animal was negative for both tests (weanling 16).  As with the 
adults, a pattern of positive serology but negative PCR results was seen in some 
animals (weanlings 1 and 13), presumably from the same cause(s).  More surprisingly, 
three animals (weanlings 10, 11 and 15) that had given positive PCR results were 
negative for anti-viral antibodies when tested some months later.  This suggests that, in 
some cases, animals can become infected and shed detectable amounts of virus, but do 
not develop a strong enough immunological “memory” for this latter to be observed in 
a serological test. 
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4 Discussion 
  Development of the PCR assay 4.1
The current method for detection of MHV and other diseases in the MSRU at Ninewells 
Hosptial is to send blood samples for serology testing using sentinel animals.  This 
study aims to address detecting a natural infection of MHV using a fast, easy and 
accurate way of testing in mouse colonies in-house by PCR.  This study demonstrates 
analysis in mouse colonies through PCR of faecal matter.  Previous methodology has 
limitations due to the infancy of PCR testing which has not been addressed. 
A standard approach to the number of faecal samples to collect from each animal, and 
to their processing for RT-PCR has been developed. The general method was validated 
by checking for the detection of genes naturally expressed in mouse epithelial cells 
(fragments of which will appear in the faecal content). A synthetic positive control 
sequence was also commissioned and gave PCR products of the expected sizes. 
Faecal samples were initially collected from 10 random weanling mice currently 
housed in various rooms in the MSRU at Ninewells hospital.  This was done a number 
of times and initial results gave positives in about 30% of cases. This was consistent 
with the historical serological detection rate in the MSRU. Sequencing of a positive PCR 
product confirmed that the MHV N-gene was indeed being detected. One of these 
positive results was used as a positive control in subsequent experiments. 
Initial experiments with a nested PCR to further amplify the signal appeared to be 
promising but, despite strenuous efforts to avoid cross-contamination, had a high rate 
of “false positives”, e.g., when water was added to the PCR reaction instead of the 
putative DNA sample. It was therefore decided to optimise a single-step PCR reaction 
(in terms of careful selection of primer sequences and the fine-tuning of temperatures). 
Even so, there were a number of occasions on which significant cross-contamination 
occurred. It has to be acknowledged that the work took place in a laboratory routinely 
handling samples from mice from the MSRU and therefore that there would have been 
a fairly constant “background”. Nevertheless, when scrupulous care was taken to 
preserve the purity of each component of the PCR reaction, reproducible results could 
indeed be obtained. 
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No attempt was made in this project to quantify the viral load in the samples, results 
were simply classed as positive, negative or faint band by visual comparison with the 
relevant controls run on the same electrophoresis gel. There are a number of 
quantitative PCR methods available now (e.g. TaqMAN), but these were not necessary 
in order to draw the conclusions reached below. 
Future work in the area of method development could include: 
1. Revisiting the “one-tube” approach to RT-PCR, to try to make the assay more 
convenient, and possibly cheaper; 
2. Moving all the analytical work to a laboratory off-site, when background 
contamination would be less of an issue; and reattempting the Nested PCR 
without using the synthetic positive control. 
3. In-depth analysis of the sequences being amplified, in order to understand their 
homology to, and likely functional differences from, those viral sequences 
already in the databases. 
4. Semi-quantitative PCR to measure viral copy number. This could be calibrated 
using the synthetic positive control DNA (though assumptions would still have 
to be made as to the efficiencies of extraction of RNA from the faecal pellets and 
its reverse transcription. 
5. Targeting another highly conserved area of the viral genome i.e., M gene. 
 
 Viral detection in animals brought into the MSRU 4.2
Given the fairly high prevalence of the virus in the animal facility as a whole (around 
30% by serology (see table 3) and my own initial PCR findings of randomly chosen 
weanling mice) and the housing of these ten animals in a heavily stocked mouse 
breeding room, we expected all the mice to become infected and to shed the virus 
within a short period of time. Other publications (Barthold, Beck et al. 1993) and 
(Casebolt, Qian et al. 1997) suggest that animals exposed to the virus should start 
shedding within a few days, though this was after direct inoculation. 
To our surprise, none of the 10 mice showed evidence of shedding the virus at any 
point over the 30 days of sampling. The straightforward detection of MHV in the 
general population suggested that this was not a problem of insufficient sensitivity. 
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It may be that adult animals are much less susceptible, even though they have no 
specific pre-existing immunity to the virus, than weanlings are to infection. C57BL/6 
mice have been claimed to be less susceptible (or at least likely to seroconvert) than 
other mouse strains to MHV (Matthaei, Berry et al. 1998), but a great majority of the 
mice in the MSRU are in this genetic background and yet MHV can routinely be 
detected in a significant minority by serology and PCR. 
When the ten mice were killed some months later and samples taken for serological 
analysis, then the majority (80%), but not all, were reported as positive. We have to 
conclude that, in those animals, either the viral load never reached levels at which the 
PCR assay could detect it, or that infection first occurred sometime after the first 30 
days of presumed exposure. 
It thus appears that MHV may fail to cause a productive infection in adult C57BL/6J 
mice for several weeks after introduction, though it may infect them at some point 
thereafter. This means that the absence of a PCR-positive result cannot be taken 
immediately to mean the absence of the virus itself, but that testing might have to 
continue for several months. Some animals may not sero-convert at all, even after 
several months of exposure. 
Future work in this area could include: 
1. Extending the faecal sampling period from 30 days to 60-90 days, or even 
longer. Note that the sampling frequency would probably have to remain daily, 
as shedding, when it does occur, can be fleeting (see below); 
2. Comparing the susceptibility of adult C57BL/6J mice with that of other inbred 
lines of laboratory mice (e.g., Balb/c); 
3. Serial blood sampling for serology over the same observation period (this 
would require licensing under the Animals (Scientific Procedures) Act 1986. 
4. Exposure of the animals to used bedding from other cages. While this might 
boost the infection rate, and is the standard practice when using “sentinel” 
animals in screening programmes, it is not representative of normal husbandry 
practices in animal units and would therefore not be informative as to the 
expected rates of transmission 
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 Viral detection in animals born in the MSRU 4.3
Three sets of breeding pairs from the 10 mice were then set up to produce off-spring in 
order to perform further testing.  There were 16 pups born and these were weaned 
after 21 days.  They were housed with their litter mates of the same sex.  Faecal 
samples were then collected from the first day after weaning for 22 days over a 30 day 
period. 
MHV was detected in 12 (75%) of the 16 weanlings tested, at some point during the 
sampling period. However, a range of outcomes was observed. In some animals, viral 
shedding was observed on only one or two consecutive days. However, in others, the 
pattern was much more complex, with continued detection being seen in some and 
cyclical shedding in others. 
There is no simple explanation of these findings. It may be that the animals still had 
variable levels of passive maternal immunity or they simply became exposed to 
“environmental” virus in different amounts and/or on different dates.  
What is clear is that there can be no safe assumptions as to how long it may take for 
this particular strain of MHV to “burn out” in the MSRU. 
Three animals tested positive for MHV by PCR but were then reported not to have 
seroconverted.  Presumably, for some reason the immune response was neither strong 
enough to prevent the second cycle of infection in weanling 10 nor to produce long-
lasting antibody levels in this animal or in weanlings 11 and 15. It is presently unclear 
why this should have happened. 
Further work should include: 
1. Isolation of mating pairs and then their offspring from the general 
environment, to determine whether offspring become infected primarily from 
their parents or from animals in adjoining cages; 
2. Repetition of the experiments on a much larger scale, to determine just how 
many patterns of infection can be expected in animals born in the unit. 
3. Application of semi-quantitative methods to determine whether “continuous” 
and “cyclical” patterns of infection are truly different phenomena. 
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 Conclusion 4.4
In terms of the original aims of the project, it is indeed possible to develop a simple and 
rapid PCR assay that detects the strain of MHV circulating in the MSRU, however 
improved sensitivity of PCR may be needed. Previous assumptions as to the rate with 
which naïve animals can become infected and the period over which an infected animal 
can continue to shed the virus have been overturned. Much more work will be required 
before the feasibility of a “fire-break” approach to the eradication of this organism can 
be assessed. Serology, while generally accurate as to the historical exposure, is not 
100% reliable.  Improved sensitivity of the PCR may also be required. 
84 
 
References 
Adami, C., J. Pooley, et al. (1995). "EVOLUTION OF MOUSE HEPATITIS-VIRUS (MHV) DURING 
CHRONIC INFECTION - QUASI-SPECIES NATURE OF THE PERSISTING MHV RNA." 
Virology 209(2): 337-346. 
Agersborg, S. S., K. M. Garza, et al. (2001). "Intestinal parasitism terminates self tolerance 
and enhances neonatal induction of autoimmune disease and memory." Eur J 
Immunol 31(3): 851-9. 
Baker, D. G. (1998). "Natural pathogens of laboratory mice, rats, and rabbits and their 
effects on research." Clin Microbiol Rev 11(2): 231-66. 
Barthold, S. W. (1986a). Research complications and state of knowledge ofrodent 
coronaviruses. Washington, Hemisphere. 
Barthold, S. W., D. S. Beck, et al. (1993). Laboratory Animal Science 43: 276-284. 
Barthold, S. W., D. S. Beck, et al. (1993). "Enterotropic coronavirus (mouse hepatitis virus) 
in mice: influence of host age and strain on infection and disease." Lab Anim Sci 
43(4): 276-84. 
Bergmann, C. C., T. E. Lane, et al. (2006). "Coronavirus infection of the central nervous 
system: host-virus stand-off." Nat Rev Microbiol 4(2): 121-32. 
Bosch, B. J., R. van der Zee, et al. (2003). "The coronavirus spike protein is a class I virus 
fusion protein: structural and functional characterization of the fusion core 
complex." J Virol 77(16): 8801-11. 
Casebolt, D. B., B. Qian, et al. (1997). "Detection of enterotropic mouse hepatitis virus fecal 
excretion by polymerase chain reaction." Lab Anim Sci 47(1): 6-10. 
Compton, S. R., S. W. Barthold, et al. (1993). "The cellular and molecular pathogenesis of 
coronaviruses." Lab Anim Sci 43(1): 15-28. 
de Groot, R. J. (2006). "Structure, function and evolution of the hemagglutinin-esterase 
proteins of corona- and toroviruses." Glycoconj J 23(1-2): 59-72. 
F R Homberger, A. L. S., and S W Barthold (1991). "Detection of rodent coronaviruses in 
tissues and cell cultures by using polymerase chain reaction." Journal of Clinical 
Microbiology 29(12): 2789-93. 
Gilbert, S. F. (2013). Developmental Biology, Sinauer Associates Inc. 
Henderson, C. J., A. R. Cameron, et al. "Evidence that the capacity of nongenotoxic 
carcinogens to induce oxidative stress is subject to marked variability." Toxicol Sci 
145(1): 138-48. 
Homberger, F. R. (1997). "Enterotropic mouse hepatitis virus." Lab Anim 31(2): 97-115. 
Homberger, F. R., L. Zhang, et al. (1998). "Prevalence of enterotropic and polytropic mouse 
hepatitis virus in enzootically infected mouse colonies." Lab Anim Sci 48(1): 50-4. 
Homberger, F. R., L. N. Zhang, et al. (1998). "Prevalence of enterotropic and polytropic 
mouse hepatitis virus in enzootically infected mouse colonies." Laboratory Animal 
Science 48(1): 50-54. 
Jacoby, R. O. and L. J. Ballgoodrich (1995). "Parvovirus Infections of Mice and Rats." 
Seminars in Virology 6(5): 329-337. 
Karst, S. M., C. E. Wobus, et al. (2003). "STAT1-dependent innate immunity to a Norwalk-
like virus." Science 299(5612): 1575-8. 
Koressaar T, R. M. (2007). "Enhancements and modifications of primer design program 
Primer3." Bioinformatics 23(10): 1289-91. 
Krzystyniak, K. and J. M. Dupuy (1984). Entry of Mouse Hepatitis Virus 3 Into Cells. 
85 
 
Kunita, S., E. Terada, et al. (1992). "Sequence analysis and molecular detection of mouse 
hepatitis virus using the polymerase chain reaction." Lab Anim Sci 42(6): 593-8. 
Kyriazis, A. P., L. DiPersio, et al. (1979). "Influence of the mouse hepatitis virus (MHV) 
infection on the growth of human tumors in the athymic mouse." Int J Cancer 
23(3): 402-9. 
Lai, M. M. (1990). "Coronavirus: organization, replication and expression of genome." Annu 
Rev Microbiol 44: 303-33. 
Lai, M. M. and D. Cavanagh (1997). "The molecular biology of coronaviruses." Adv Virus Res 
48: 1-100. 
Leiter, E. H., P. H. Le, et al. (1988). "Genetic and environmental control of diabetes 
induction by multi-dose streptozotocin in two BALB/c substrains." Diabetes Res 
9(1): 5-10. 
Lorenz, T. C. (2012). "Polymerase chain reaction: basic protocol plus troubleshooting and 
optimization strategies." J Vis Exp(63): e3998. 
Mahler (Convenor), M., M. Berard, et al. (2014). "FELASA recommendations for the health 
monitoring of mouse, rat, hamster, guinea pig and rabbit colonies in breeding and 
experimental units." Lab Anim 48(3): 178-192. 
Matthaei, K. I., J. R. Berry, et al. (1998). "Use of polymerase chain reaction to diagnose a 
natural outbreak of mouse hepatitis virus infection in nude mice." Lab Anim Sci 
48(2): 137-44. 
Nicklas, W., V. Kraft, et al. (1993). "Contamination of transplantable tumors, cell lines, and 
monoclonal antibodies with rodent viruses." Lab Anim Sci 43(4): 296-300. 
Ning, Q., S. Lakatoo, et al. (2003). "Induction of prothrombinase fgl2 by the nucleocapsid 
protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear 
factor-4 alpha." J Biol Chem 278(18): 15541-9. 
Nuttall, P. A. and K. A. Harrap (1982). "Isolation of a coronavirus during studies on 
puffinosis, a disease of the Manx shearwater (Puffinus puffinus)." Arch Virol 73(1): 
1-13. 
Oyanagi, M., A. Kato, et al. (2004). "Detection of MHV-RNAs in mouse intestines and in 
filter dust in mouse room ventilation duct by a modified RT-nested PCR." Exp Anim 
53(1): 37-41. 
Pachuk, C. J., P. J. Bredenbeek, et al. (1989). "Molecular cloning of the gene encoding the 
putative polymerase of mouse hepatitis coronavirus, strain A59." Virology 171(1): 
141-8. 
Percy, D., Barthold SW, Ed. (2007). Pathology of Laboratory Rodents and Rabbits. Iowa, 
Blackwell Publishing Professional. 
Raamsman, M. J., J. K. Locker, et al. (2000). "Characterization of the coronavirus mouse 
hepatitis virus strain A59 small membrane protein E." J Virol 74(5): 2333-42. 
Rao, G. N., W. W. Piegorsch, et al. (1989). "Influence of viral infections on body weight, 
survival, and tumor prevalence of B6C3F1 (C57BL/6N x C3H/HeN) mice in 
carcinogenicity studies." Fundam Appl Toxicol 13(1): 156-64. 
Richter, C. B., J. E. Thigpen, et al. (1988). "Fatal pneumonia with terminal emaciation in 
nude mice caused by pneumonia virus of mice." Lab Anim Sci 38(3): 255-61. 
Skinner, M. A. and S. G. Siddell (1983). "Coronavirus JHM: nucleotide sequence of the 
mRNA that encodes nucleocapsid protein." Nucleic Acids Res 11(15): 5045-54. 
Smith, A. L., V. A. Carrano, et al. (1984). "Response of weanling random-bred mice to 
infection with pneumonia virus of mice (PVM)." Lab Anim Sci 34(1): 35-7. 
Smith, A. L., R. O. Jacoby, et al. (1993). "In vivo studies with an "orphan" parvovirus of 
mice." Lab Anim Sci 43(2): 175-82. 
86 
 
Sturman, L. S., C. S. Ricard, et al. (1985). "Proteolytic cleavage of the E2 glycoprotein of 
murine coronavirus: activation of cell-fusing activity of virions by trypsin and 
separation of two different 90K cleavage fragments." J Virol 56(3): 904-11. 
Taffs, L. F. (1976). "Pinworm infections in laboratory rodents: a review." Lab Anim 10(1): 1-
13. 
Uetsuka, K., H. Nakayama, et al. (1996). "Hepatitogenicity of three plaque purified variants 
of hepatotropic mouse hepatitis virus, MHV-2 in athymic nude mice." Exp Anim 
45(2): 183-7. 
Untergrasser A, C. I., Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG (2012). "Primer3 - 
new capabilities and interfaces." Nucleic Acids Research 40(15): e115. 
Virelizier, J. L., A. M. Virelizier, et al. (1976). "The role of circulating interferon in the 
modifications of immune responsiveness by mouse hepatitis virus (MHV-3)." J 
Immunol 117(3): 748-53. 
Wang, R. F., W. L. Campbell, et al. (1999). "Diagnosis of mouse hepatitis virus 
contamination in mouse population by using nude mice and RT-PCR." Mol Cell 
Probes 13(1): 29-33. 
Weir, E. C., D. G. Brownstein, et al. (1988). "Respiratory disease and wasting in athymic 
mice infected with pneumonia virus of mice." Lab Anim Sci 38(2): 133-7. 
Weiss, S. R. and J. L. Leibowitz (2011). "Coronavirus pathogenesis." Adv Virus Res 81: 85-
164. 
Wilberz, S., H. J. Partke, et al. (1991). "Persistent MHV (mouse hepatitis virus) infection 
reduces the incidence of diabetes mellitus in non-obese diabetic mice." 
Diabetologia 34(1): 2-5. 
Wunderlich, M. L., M. E. Dodge, et al. "Multiplexed fluorometric immunoassay testing 
methodology and troubleshooting." J Vis Exp(58). 
Yamada, Y. K., M. Yabe, et al. (1998). "Application of nested polymerase chain reaction to 
detection of mouse hepatitis virus in fecal specimens during a natural outbreak in 
an immunodeficient mouse colony." Exp Anim 47(4): 261-4. 
Yokomori, K. and M. M. Lai (1991). "Mouse hepatitis virus S RNA sequence reveals that 
nonstructural proteins ns4 and ns5a are not essential for murine coronavirus 
replication." J Virol 65(10): 5605-8. 
Yu, X., W. Bi, et al. (1994). "Mouse hepatitis virus gene 5b protein is a new virion envelope 
protein." Virology 202(2): 1018-23. 
 
 
